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1. Introduction 
Multidrug resistance (MDR) is a major clinical obstacle in the 
treatment of several cancers including hematological 
malignancies and solid tumors. The ATP-binding cassette 
transporter P-glycoprotein (P-gp, ABCB1), is one molecule that 
is involved in drug resistance.1 Cancer cells can escape from the 
toxic effect of drugs mainly due to the highly expressed 
membrane transporters that pump drugs out of cells.2 To 
overcome P-gp mediated MDR, modulators, so called P-gp 
inhibitors, can be used to block efflux pump activity. P-gp 
inhibitors can be used in combination with anticancer drugs to 
enhance the effectiveness of chemotherapy against resistant 
tumor cells. On the other hand, P-gp is presented in normal 
tissues, thus non-selective blockage of P-gp can cause undesired 
side effects. Therefore, it is important to deliver P-gp inhibitor 
only to the tumor cells (along with anticancer drug) and limit its 
distribution in the body. Much effort has been devoted to 
developing P-gp inhibitors to modulate MDR. However, none of 
the inhibitors on the market have been successful. Three 
generations of inhibitors have been developed in order to reverse 
MDR. First-generation inhibitors including verapamil, and 
cyclosporine A were limited by unacceptable toxicity.3 Second- 
generation agents such as dexverapamil, PSC833 had better 
tolerability but displayed unwanted pharmacokinetic interactions. 
Third-generation inhibitors can specifically and potently inhibit 
P-gp function, several of them have been tested in controlled 
clinical trials, but no satisfactory results have been obtained.4 For 
almost three decades, research has been conducted to overcome 
MDR through pharmacological inhibition of ABC transporters 
with limited clinical success. Therefore it is still urgent to 
develop some new agents to overcome MDR.5  
During the recent years, investigation of inhibition of multi-
drug resistance (MDR) attracted an increased interest world-
wide.6 Among the effective compounds that proved to inhibit 
resistance, some phenothiazine derivatives were found of high 
activity.7 With some of the most important such compounds 
involving chloropromazine8, trifluoperazine9, thioridazine10, two 
common structural features of these compounds should be 
pointed out: (i) presence of an alkyl chain attached to the nitrogen 
atom of the phenothiazine ring; (ii) presence of an amino moiety 
in most of the derivatives. 
Earlier, we described a novel synthetic approach to N-
dienylphenothiazines11 and, quite recently, reduction of these 
compounds to N-butyl and N-hydroxybutyl derivatives12 has been 
reported. Even if the MDR inhibitory efficacy of these new 
compounds proved to be only moderate, further functionalization 
of these derivatives seemed promising in order to discover new 
potent MDR inhibitors among the newly synthesized 
phenothiazine derivatives.  
2. Results and Discussion 
2.1. Synthesis 
In this paper we report on a well executable synthetic protocol 
to N-tetrazolylbutylphenothiazines bearing various amino 
functions in position 2 of the tricyclic ring as well as on 
biological evaluation of the new derivatives. 
Two of our recent findings provided proper starting point in 
order to perform the above planned transformations: a) the 
successful reduction of phenothiazinyldienes to the related butyl 
compounds by borane12 and, b) the convenient introduction of 
amino groups into the desired position of phenothiazine by 
Buchwald-Hartwig cross-coupling reaction of the commercially 
available 2-chlorophenothiazine.13a 
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 By utilization of these structural conversions, the synthetic 
strategy route “A” starting from the easily accessible 
dienylphenothiazine (1) shown in Scheme 1 seemed 
straightforward, i.e. Buchwald-Hartwig amination to 2 followed 
hydroboration-oxidation to give the saturated monohydroxy 
product (3). As pharmacological measurements indicated that, 
concerning the MDR modulatory activity, those compounds 
bearing a 4-methoxyphenyl group on the N2 atom of the tetrazole 
ring are superior and, thus, all further chemical transformations 
have been carried out with such methoxy compounds (c.f. Table 
2 later in this publication). 
Scheme 1 reveals these transformations proceeded in medium 
to low yield only and, in some cases, decomposition was 
experienced and no product could be isolated (Table 1). It is 
interesting to note that in one case: with the diethylamino 
derivative 2f, the expected product 3f was found as a minor 
component of the reaction mixture, whereas a sulfoxide (4f) was 
formed in majority (67%). A specific NMR spectral feature of 
this product is appearance of two sets of signals due to the 
presence of two chiral centers (i.e. the secondary alcohol and 
sulfoxide moeties). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthetic route “A” to N-(2-hydroxybutyl)-2-aminophenothiazines (3). 
 
  
Table 1. Used primary/secondary amines and acid amides in 
the synthesis of N-(2-hydroxybutyl)-2-aminophenothiazines 
(3) via route A (Scheme 1). 
 
 
The above findings prompted us to apply another synthetic 
strategy and, thus, route “B” was decided next (Scheme 2). This 
route involved the hydroboration-oxidation of the diene (1) to the 
hydroxybutyl derivative (5) as described in our recent 
publication12, followed by protection of the OH group (formation 
of 6 by benzylation). Also, an alternative route “C” was applied 
by reacting 5 with tert-butyldiphenylchlorosilane (tBuPh2SiCl) to 
give the O-protected 2-chlorophenothiazine compound 8. 
Formation of the benzyloxy and tert-butyldiphenylsilyloxy 
compounds (6 and 8) was accomplished according to analogous 
procedures described in the literature.14,15 
Both O-protected compounds (6 and 8) were subjected to 
Buchwald-Hartwig amination to give the amines 7 and 9, 
respectively. In contrast to the poor yields experienced in route 
“A” with the transformation 1  3 (Scheme 1), the cross-
coupling amination of 6 and 8 was found to proceed in good to 
excellent yields (44-93%) in most cases: Pd2(dba)3 or Pd(OAc)2 
were used as the Pd-catalysts in the presence of NaOtBu, Cs2CO3 
or K2CO3 as a base, the ligand was XPhos in every case, whereas 
toluene or 1,4-dioxane were used as a solvent. 
The amino components involved primary amines (a-e), 
secondary amines (f-k), and two amides (l, m) as specified in 
Scheme 1. 
Finally, deprotection of 7 and 9 by acidic treatment and 
reaction with TBAF, respectively, by using literature 
procedures16 yielded the free hydroxy group containing products 
(3a-m). Table 2 summarizes all 2-aminophenothiazines prepared 
by route “B” or “C”. Inspection of this table reveals that the best 
yields were obtained with route “C”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthetic route “B”and “C” to N-(2-hydroxybutyl)-2-
aminophenothiazines (3). 
 
The aforementioned finding with formation of a sulfoxide (4f) 
in course of the hydroboration-oxidation reaction directed our 
attention to a deeper study on synthetic possibilities to such 
compounds. Inspection of the pertinent literature revealed that 
relatively few data on phenothiazine-sulfoxides exist. Thus, 
oxidation to phenothiazinyl sulfoxides,17,18,19 and sulfones20,21 has 
been reported. Also, selective procedures to sulfoxides and 
sulfones have been described.22 
In order to prepare a series of amine-containing sulfoxides 
(e.g. 4f) the chloro compound 5 was first oxidized by m-CPBA to 
the 2-chlorosulfoxide 1022 (Scheme 3) and, then this compound 
was subjected to Buchwald-Hartwig cross-coupling reaction with 
three selected secondary amines to give 4h,i. Most interestingly, 
reaction of 10 with diethylamine resulted in dehalogenation to 
yield the 2-unsubstituted compound 11. The structures of 4h,i 
involve two chirality centers (i.e. the secondary alcohol function 
and the novel of the sulfoxide moiety) and, accordingly, in the 
1H-NMR spectra two sets of resonances corresponding to the two 
diastereomers appeared. Attempts for further oxidation of these 
sulfoxides, unfortunately, failed and prologued oxidation of 4h 
resulted in formation of an N-oxide (12) rather than the expected 
sulfone.
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Table 2. Comparison of yields obtained via routes “B” and “C” depicted in Scheme 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthetic routes to preparation of sulfoxide and sulfone derivatives. 
Entry HNR1R2 
Route ”B” Route “C” 
Buchwald-Hartwig 
amination 7 (%) 
Debenzylation 
3 (%) 
Buchwald-Hartwig 
amination 9 (%) 
Desilylation 
3 (%) 
a  - - 84 91 
b 
 
- - 93 84 
c  67 quant. - - 
d 
 
64 - - - 
e  - - 57 49 
f  - - 57 86 
g  - - - - 
h  - - 91 87 
i  99 33 73 64 
j  - - - - 
k  80 62 - - 
l 
 
29 - 64 quant. 
m 
 
- - 44 96 
  
In order to circumvent this problem, the silylated 2-chloro 
compound 8 was oxidized to a sulfoxide (13) and, then, a 
further oxidation of 13 by m-CPBA under more forced 
conditions yielded the O-protected 2-chlorophenothiazine 
sulfones (14). Subsequent Buchwald-Hartwig amination with 
secondary amines to 15f,h,i and the cleavage of protecting 
group provided the desired 2-aminophenothiazinyl sulfones 
(16f,h,i) in high yields. 
As revealed by the biological assays as discussed below, 3h 
proved to be one of the most active MDR inhibitor (exceeding 
the efficacy of that of verapamil). As the above discussed 
synthesis provided this compound as a racemic mixture, 
separation of the enantiomeric pairs was decided. Among the 
several possible resolution strategies, application of the 
semiequivalent method was decided.23 To this end, 5 was first 
functionalized by reaction of the hydroxy group with maleic 
acid anhydride to give semiacid (17). A solution of this 
compound in ethyl acetate was treated with a half equivalent of 
S-(-)-phenylethylamine in order to obtain a mixture of 
diastereomeric salts. The (-)-diastereomeric salt (18) 
precipitated from the mixture, whereas the dissolved (-)-
diastereomeric salt and the (+)-monoester (19) remained in the 
solution. The crystalline 18 was filtered off and, after several 
recrystallizations, it was hydrolyzed to the (-)-monoester ((-)-
17). Saponification of (-)-17 with sodium hydroxide solution 
under reflux afforded the optically pure (-)-hydroxy compound 
((-)-5) with excellent enantiomeric purity (ee.: 99.9). Similar 
work-up of the solution containing mainly 19 via formation of 
(+)-monoester (+)-17 resulted in isolation of the (+)-
enantiomer of 5 with lower optical purity (ee: 74-98%) 
(Scheme 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Resolution of racemic 5 to enantiomers. 
 
The obtained optically pure (-)-5 and (+)-5 were suitable 
starting materials for preparation of those amines (i.e. (3f,h,i) 
that seemed to be promising lead candidates on the basis of 
biological evaluations (see below section). To this end, route 
“C” was applied. Accordingly, (-)-5 and (+)-5 were silylated 
to (-)-8 and (+)-8, Buchwald-Hartwig amination yielded the O-
protected amines (-)-9f,h,i- and (+)-9f,h,i and, finally, 
deprotection afforded the desired (-)-3f,h,i and (+)-3f,h,i 
(Scheme 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. Synthesis of (-)-3f,h,i and (+)-3f,h,i derivatives applying route 
“C”. 
 
2.2. P-gp interaction studies 
The above discussed set of N-substituted phenothiazine 
derivatives was tested for P-gp inhibitor activity in primaty rat 
hepatocyte culture. The rate of rhodamine 123 (RH123) 
accumulation was studied in the presence of these molecules 
and of verapamil, a commonly used P-gp inhibitor. All 
compounds were studied at 10 µM concentration, and data are 
expressed as % of the inhibition by verapamil.  
Table 3. Comparison of the effects of R1 and R2 of 
derivatives 1, 20a-e on the RH123 accumulation. 
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R1 R2 compound Inhibition of RH123 efflux  (% of the effect of 10 µM verapamil) 
H Cl 20a7 < 25 
H OCH3 20b7 25 <; < 75 
Cl Cl 20c7 < 25 
Cl OCH3 1 25 <; < 75 
CF3 OCH3 20d7 25 <; < 75 
CF3 COOEt 20e < 25 
 Table 3 demonstrates the inhibitor activity of three pairs of 
derivatives having hydrogen, chloro atoms, and trifluoromethyl 
group on position 2 of the phenothiazine ring, whereas 
substituents on the phenyl ring attaching to N2 of the tetrazol 
involved chloro, methoxy, and ethoxycarbonyl groups (1, 20a-
d). These data reveal that molecules containing 4-
methoxyphenyltetrazole moiety were found to be most 
effective, irrespective of the substituents on position 2 of the 
phenothiazine ring even if the rate of inhibition was 
considerably influenced by substituents on the latter position.  
A further variety of N-2-hydroxybutylphenothiazine 
compounds, all containing a 4-methoxyphenyl group on the 
tetrazole ring and differently substituted amino groups on 
position 2 of phenothiazine is shown in Table 4. P-gp inhibitor 
capacity of some of these derivatives (3f, 3h, 3m) was 
comparable to that of verapamil. 
Table 4. Comparison of inhibition of RH123 accumulation 
by of N-hydroxyalkyl-2-aminophenothiazines 3a-m. 
 
 
 
 
 
 
 
 
 
* highest activity, concentration-dependence was also studied, see 
Figures 2-4 
As revealed by the above data, the 2-butanol part of 
phenothiazine derivatives 3 was essential for a potent P-gp 
inhibition. This part of the molecule contains a chirality center. 
As chirality of many compounds has an impact on their protein 
binding, we have investigated whether the use of stereoisomers 
of the most potent derivatives alters their inhibitor property. 
For this purpose, products of resolution of two derivatives 
(3h,i) each isolated as pure enantiomers ((+)-3h, (-)-3h, (+)-3i, 
(-)-3i) have been selected and their activity has been compared 
with that of the related racemic form as well as with verapamil. 
As shown in Figure 1 there was no significant difference in 
RH123 accumulation in the presence of either the racemic or 
any of the stereoisomer derivatives of these compounds. 
 
 
 
 
 
 
 
 
 
Figure 1. Comparison of P-gp interaction activity of racemic 
phenothiazines and their stereoisomer counterparts. 
 
Oxidation of the sulfur atom of the phenothiazine ring 
further improved the inhibitor potency of the molecules (Table 
5). Two of these derivatives (4h, 16h) proved to be 
significantly better P-gp inhibitors than verapamil. 
 
Table 5. Comparison of inhibition of RH123 accumulation 
by sulfoxide and sulfone derivatives of 2-aminopheno-
thiazines 11, 10, 4f,h,i, 16f,h,i. 
 
 
 
 
 
 
 
* highest activity, concentration-dependence was also studied, see 
Figures 2-4 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison of RH123 accumulation in the presence of 3f, 
3h, and verapamil. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Comparison of RH123 accumulation in the presence of 3b, 
3f, 3i, 3h, 4h, and verapamil. 
 
The concentration dependence concerning P-gp interactions 
of the most potent compounds was compared to that of 
verapamil. No significant difference was found between the 
effect of 3f, 3h and verapamil up to 50 µM (Figure 2). In order 
to gain a more precise relationship between the inhibitor 
capacity and molecular structure of the derivatives, their 
Compound Inhibition of RH123 efflux (% of the effect of 10mM verapamil) 
3a > 75 
3b > 75     * 
3c 25 <; < 75 
3d 25 <; < 75 
3e 25 <; < 75 
3f ≈ 100   * 
3g < 25 
3h ≈ 100   * 
3i > 75     * 
3j < 25 
3k 25 <; < 75 
3l > 75 
3m ≈ 100 
Compound Inhibition of RH123 efflux (% of the effect of 10mM verapamil) 
11 > 75 
10 > 75 
4f > 75 
4h > 100  * 
4i 25 <; < 75  
16f >75 
16h >100  * 
16i > 75 
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 influence at a lower (up to 10 mM) concentration range was 
also studied. No remarkable difference between the actions of 
this set of compounds was observed; the rate of inhibition was 
comparable to that of verapamil. In case of sulfoxide derivative 
(4f) – obtained first as an unexpected product of 
hydroboration-oxidation, a slight, but significant increase in P-
gp inhibition could be observed (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Comparison of RH123 accumulation in the presence of 3h, 
4h, 16h, and verapamil. 
 
This latter finding directed our attention to the study of the 
effect of oxidation of the sulfur atom in the phenothiazine ring 
as shown in Figure 4. The number of oxygen atoms attached to 
the sulfur atom had an impact on the interaction potential of 
the molecule. Compared to 3h, one additional oxygen atom 
(i.e. the sulfoxide 4h) slightly, but significantly, and a second 
oxygen atom (i.e. the sulfone 16h) considerably increased the 
accumulation of RH123. 
2.3. Cytotoxicity assays 
MTT assay was used to assess cell viability, cytotoxicity. 
These assays were performed with the most potent P-gp 
inhibitor compounds (3h, 3f, 3b, 4h, 16h). The viability of the 
hepatocytes as shown in Figure 5 did not change, so the 
observed decrease of the P-gp activity was not due to cytotoxic 
effects in the presence of any of these derivatives. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Results of the viability (MTT) assays.  
 
Hepatocytes were treated for 3 hours with 10 μM of 3h, 3f, 
3b, 4h, 16h or the vehicle (control), respectively. Data are 
shown as % of the control. 
Conclusion 
Hydroboration-oxidation of dienylphenothiazines and 
Buchwald-Hartwig cross-coupling reaction of 2-chloro 
derivatives allowed the synthesis a set of new N-2-
hydroxybutylphenothiazines and their sulfoxides and sulfone 
derivatives. The structure of these compounds has been 
systematically modified at those positions that have been 
shown to have an impact on the rate of P-gp inhibitor activity 
of the molecule. The extent of inhibition by the most potent 
derivatives slightly exceeded that of verapamil, a well-known 
P-gp inhibitor. A high variety of efficacy was observed as a 
function of the quality of substituents on position 2 of the 
phenothiazine and the phenyltetrazole moiety. The N-2-
hydroxybutyl chain proved to be essential for the interaction 
with P-gp. The sulfone derivative 16h exhibited the highest 
efficacy. MTT assays revealed that the new MDR inhibitory 
compounds are not toxic. 
3. Experimental Section  
Cytotoxicity assays 
MTT is added directly to the culture medium and is reduced 
by metabolically active cells to insoluble purple formazan dye 
crystals. The absorbance of the sample is read directly in the 
wells at an optimal wavelength of 570 nm. The amount of 
formazan produced is in direct proportion to the viability of the 
cells. After treatment with the compounds indicated at 10 μM, 
or with the vehicle (control) for 3 h, hepatocytes were washed 
and incubated with 1 mg/mL MTT for 2 h. Then the cells were 
lysed with 1 mL of DMSO and the absorbance was measured 
at 570 nm using a microplate reader. Data are shown as % of 
the control. 
Method for determination of P-gp inhibitor properties. 
 
   P-gp interaction of the phenothiazine derivatives was studied 
in a conventional monolayer culture of primary rat 
hepatocytes. Hepatocytes were prepared from male Wistar rats 
(200-250 g) (Charles River, Budapest) by two-step, in situ liver 
collagenase perfusion according to the method of Seglen.24 
Cell viability (> 90%) was determined by trypan blue 
exclusion. All procedures were approved by the Institutional 
Animal Care and Use Committee. Hepatocytes were plated at a 
density of 1.9 x 105 cells/cm2 in 24-well plates precoated with 
rat tail collagen in Williams Medium E containing 5% of fetal 
calf serum, 100 nM insulin, 0.1 mg/ml gentamicin, 30 nM 
Na2SeO3, and 0.1 M dexamethasone. Calf serum was present 
for the first 24 h then omitted. Cells were maintained at 37 °C 
in a humidified atmosphere of 95% air-5% CO2. In 1 h after 
plating, and every day thereafter, the medium was changed to 
Williams Medium E supplemented with insulin, gentamicin, 
dexamethasone, Na2SeO3. The RH123 accumulation assay was 
performed as described previously,12 briefly, at 4 days after 
plating cells were washed and preloaded with 5 M RH123 in 
Williams’ Medium E for 30 min. Then the hepatocytes were 
washed three times with an ice cold Hanks Balaced Salt 
Solution (HBSS) and incubated with RH123 free Williams’ 
Medium E containing the phenothiazine derivatives, verapamil 
at different concentrations, or the vehicle as control (0.1% 
DMSO), respectively for 3 h. Subsequently, the cells were 
washed with ice cold HBSS and were lysed with 0.5% of 
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 Triton X100/HBSS. The intracellular RH123 concentration 
was measured fluorimetrically at 519/538 nm.  
 
The results are expressed as mean ± SD for all experiments. 
Triplicate experiments of three independent hepatocyte 
isolations were run, and four wells were used for each set of 
conditions. Statistical analysis was performed using the 
Student’s t-test. 
 
Chemistry 
Melting points were determined on a Büchi apparatus and 
are uncorrected. The IR spectra were recorded on a Thermo 
Nicolet Avatar 320 FT-IR spectrometer. NMR experiments 
were carried out on 300 MHz (for 1H) and 400 MHz (for 1H) 
Varian NMR SYSTEM spectrometers by using 5 mm Z 
gradient auto tunable probes. Measurements were performed at 
+25 °C in CDCl3 or DMSO-d6. 1H and 13C-NMR spectra are 
referenced to residual solvent signals. For the complete 1H, 13C 
assignments standard 1D and homo and heterocorrelation 2D 
measurements were performed. The elemental analysis has 
been carried out with an Elementar Vario EL III apparatus (at 
the Analytical Laboratory for Organic Chemistry, Institute of 
Organic Chemistry, Research Centre for Natural Sciences, 
Hungarian Academy of Sciences, Pusztaszeri út 59, H-1025 
Budapest, Hungary). The exact mass measurements were 
performed using a Q-TOF Premier mass spectrometer (Waters 
Corporation, 34 Maple St, Milford, MA, USA) in positive 
electrospray mode. Enantiomeric purities of the compounds 
were determined by chiral HPLC method. The chiral 
separation was performed with a system composed of a Jasco 
PU-980 pump, a Rheodyne 7125 injector (20 l loop), a Jasco 
MD 2010 Plus UV/Vis photodiode-array detector (at 260 nm) 
and a ChromPass chromatographic software. Successful 
separation of compounds 3f, 3h, 3i, 5 (-OH derivatives) and 
the protected –Cl (8) was performed on a Chiralpak AD 
column (250 x 4.6 mm I.D. Daicel Chemical Ind. Tokyo, 
Japan). The mobile phase was 70% n-hexane, 30% 2-propanol 
with 0.1% diethylamine and 98% n-hexane, 2% 2-propanol 
with 0.1% diethylamine for 8, the flow rate was 1 mL/min. The 
basic protected compounds (9f, 9h, 9i) were analysed on a 
LUX-Amylose-2 column (250 x 4.6 mm I.D. Phenomenex 
Inc., USA). The mobile phase was 75% n-hexane, 25% 2-
propanol with 0.1% diethylamine, the flow rate was 1 mL/min. 
Optical rotation values were determined on AA-10R and 
JASCO P-2000 polarimeters, (λ= 589 nm). Chromatographic 
separations were carried out on silica gel (60 H, Merck). 
Reactions were monitored with Merck silica gel 60 F254, TLC 
plates (0.25 mm thickness). BH3xMe2S (borane-dimethyl 
sulfide complex) >90% in dimethyl sulfide was purchased 
from Sigma-Aldrich.  All the chemicals and solvents were used 
as supplied. 
General procedure for the synthesis of 1-(2-amino-10H-
phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butan-2-ol (3) derivatives by hydroboration-oxidation of 
dienes 2.  Route „A” 
To a solution of the appropriate 10-{(1E,3Z)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]buta-1,3-dien-1-yl}-10H-
phenothiazin-2-amine (2, 4 mmol) in abs. THF (40 mL) in a 
dried, round-bottomed flask equipped with a side arm and 
cooled to 0 °C in an argon atmosphere was added BH3xMe2S 
(1.6 mL, 16 mmol) dropwise by injection. After addition, the 
resulting yellow suspension was allowed to warm up to rt and 
maintained at this temperature for prolongued time. After the 
completion of the reation (1 d, monitored by TLC), the 
reaction mixture was cooled to 0 °C with an ice bath, and 
treated with methanol (30 mL), 10% aqueous NaOH (2 mL) 
and H2O2 (30% aqueous solution, 2 mL). This mixture was 
then stirred at rt for 1 d. The solution was then poured onto ice 
cold water, neutralized with 10% aqueous HCl and extracted 
with dichloromethane (3 x 30 mL). The combined organic 
phase was dried over anhydrous Na2SO4, filtered and 
concentrated. The residue was purified by flash 
chromatography on silica gel using the eluent dichloromethane 
then n-hexane:ethyl acetate = 2:1. The crude product (foam) 
was triturated with diethyl ether, the mixture was cooled 
whereupon a solid product deposited. The product was 
collected by filtration. 
General procedure for preparation of 1-(2-amino-10H-
phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butan-2-ol derivatives (3a-k) as well as the related 
amides (3l,m) by debenzylation of 10-{2-(benzyloxy)-4-[2-
(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-10H-
phenothiazin-2-amine/amide derivatives (7) Route „B” 
To the clear solution of 10-{2-(benzyloxy)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl}-10H-phenothiazin-2-
amine/amide (7, 0.08 mmol) in ethanol (1.2 mL) was added cc. 
HCl (1.2 mL) dropwise, very slowly and the reaction mixture 
was refluxed for 4-6 d. The mixture was concentrated under 
reduced pressure. The residue was dissolved in water (2 mL), 
neutralized with cc. NaHCO3 solution and extracted with 
dichloromethane (3 x 3 mL). The organic phase was dried over 
Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography on silica gel using the 
eluent n-hexane:ethyl acetate = 2:1 then 1:1 to give the final 
product as a solid. 
General procedure for preparation of 1-(2-amino-10H-
phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butan-2-ol derivatives (3a-k) as well as the related 
amides (3l,m) by desilylation of 10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-10H-phenothiazin-2-amine/amide 
derivatives (9) Route „C” 
To the solution 10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-
(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-
2-amine/amide (9, 0.14 mmol) in anhydrous THF (1 mL) in a 
dried, round-bottomed flask equipped with a side arm and 
cooled to 0 °C in an argon atmosphere was added the solution 
of TBAF (0.20 mmol) in abs. THF (1 mL). After  48 h, the 
reaction mixture was allowed to warm up to rt and the reaction 
the mixture was evaporated. The residue was purified by 
column chromatography on silica gel using the eluent 
chloroform:methanol = 50:1, then 20:1 to give the product. 
1-(2-{[2-(Dimethylamino)ethyl]amino}-10H-
phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butan-2-ol (3a) 
According to route „C”, this compound was obtained from 
N'-[10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-2-
yl]-N,N-dimethylethane-1,2-diamine (9a, 0.11 g) as a beige 
amorphous solid, 76 mg (91%); mp 56-58 °C; (Found: C, 
63.01; H, 6.18; N, 18.38; C28H33N7O2S requires C, 63.25; H, 
6.26; N, 18.44%); m/z (EI) [M+H]+: 532.20 (C28H33N7O2S 
requires 531.24); νmax (KBr)/cm-1: 3368, 2930, 1601, 1516 and 
1464; δH (300 MHz, CDCl3) 2.05 (1H, m), 2.21 (1H, m), 2.24 
(6H, s), 2.47 (1H, m), 2.54 (2H, t, J = 7.8 Hz), 3.09-3.22 (4H, 
m), 3.85 (3H, s), 3.87 (1H, m), 4.07 (1H, m), 4.18 (1H, m), 
 4.25 (1H, m), 6.25-6.27 (2H, m), 6.89-7.19 (7H, m), 7.97 (2H, 
m); δC (75 MHz, CDCl3) 21.9, 32.2, 41.1, 45.1 (2C), 53.8, 55.6, 
57.8, 66.5, 101.9, 107.8, 113.0, 114.6 (2C), 116.1, 121.3 (2C), 
122.8, 126.9, 127.6, 128.0, 128.2, 130.4, 145.5, 146.7, 148.6, 
160.4, 166.5. 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-{2-[(2-
morpholin-4-ylethyl)amino]-10H-phenothiazin-10-
yl}butan-2-ol (3b) 
According to route „A”, this compound was obtained from 
10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]buta-
1,3-dien-1-yl}-N-(2-morpholin-4-ylethyl)-10H-phenothiazin-2-
amine (2b, 2.22 g) as yellow amorphous solid,  0.6 g (26%). 
According to route „C”, this compound was obtained from 
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-N-(2-morpholin-4-
ylethyl)-10H-phenothiazin-2-amine (9b, 0.12 g) as yellow 
amorphous solid, 85 mg (84%); mp 65-68 °C; (Found: C, 
63.19; H, 6.06; N, 16.90; C30H35N7O3S requires C, 62.81; H, 
6.15; N, 17.09%); m/z (EI) [M+H]+: 574.10 (C30H35N7O3S 
requires 573.25); νmax (KBr)/cm-1: 3374, 2933, 1601, 1515 and 
1464; δH (300 MHz, CDCl3) 2.03 (1H, m), 2.20 (1H, m), 2.34-
2.43 (4H, m), 2.58 (2H, t, J = 5.9 Hz), 2.85 (1H, br. s), 3.07-
3.19 (4H, m), 3.68 (4H, t, J = 4.3 Hz), 3.86 (3H, s), 3.88 (1H, 
m), 4.04 (1H, m), 4.20 (1H, m), 4.22 (1H, m), 6.24-6.26 (2H, 
m), 6.89-7.02 (5H, m), 7.13 (2H, m), 7.95 (2H, m); δC (75 
MHz, CDCl3) 22.1, 32.5, 40.3, 53.5 (2C), 54.0, 55.9, 57.2, 
66.7, 67.1 (2C), 102.1, 108.1, 113.5, 114.9 (2C), 116.4, 121.6 
(2C), 123.1, 127.2, 127.9, 128.2, 128.5, 135.0, 145.7, 147.0, 
148.8, 160.6, 166.7. 
 
1-[2-(Benzylamino)-10H-phenothiazin-10-yl]-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (3c) 
According to route „A”, this compound was obtained from 
N-benzyl-10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]buta-1,3-dien-1-yl}-10H-phenothiazin-2-amine (2c, 2.10 g) 
as a brown oil, 0.65 g (30%). 
According to route „B”, this compound was obtained from 
N-benzyl-10-{2-(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl}-10H-phenothiazin-2-amine (7c, 0.05 g, 
0.08 mmol) as a brown oil, 42 mg (quant.); (Found: C, 67.42; 
H, 5.83; N, 15.06; C31H30N6O2S requires C, 67.61; H, 5.49; N, 
15.26%); HRMS calcd for C31H30N6O2S 550.2151 found: 
550.2151; m/z: 534 (87%), 506 (22), 464 (6), 385 (98), 352 
(26), 330 (9), 303 (100), 267 (13), 213 (28), 185 (63), 160 (15), 
123 (49) and 91 (74); νmax (film)/cm-1: 3381, 2928, 1600, 1515 
and 1257; δH (300 MHz, CDCl3) 1.97 (1H, m), 2.11 (1H, m), 
2.66 (1H, br. s), 3.06-3.17 (2H, m), 3.78 (1H, dd, J = 13.0, 9.0 
Hz), 3.87 (3H, s), 3.95 (1H, dd, J = 13.0, 3.2 Hz), 4.07 (1H, 
m), 4.15 (1H, br. s), 4.29 (2H, s), 6.22-6.29 (2H, m), 6.87-7.03 
(5H, m), 7.09-7.19 (2H, m), 7.26-7.36 (5H, m), 7.96 (2H, m); 
δC (75 MHz, CDCl3) 22.1, 32.3, 48.6, 54.0, 55.9, 66.6, 102.1, 
108.3, 113.7, 114.8 (2C), 116.3, 121.5 (2C), 123.1, 127.2, 
127.5 (2C), 127.8, 128.1, 128.5, 128.9 (2C), 130.7, 139.4, 
145.9, 146.6, 148.4 (2C), 160.6, 166.7. 
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-{[(1R)-1-
phenylethyl]amino}-10H-phenothiazin-10-yl)butan-2-ol 
(3d) 
According to route „A”, this compound was obtained from 
10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]buta-
1,3-dien-1-yl}-N-[(1R)-1-phenylethyl]-10H-phenothiazin-2-
amine (2d, 2.19 g) as beige amorphous solid, 1.04 g (46%); 
mixture of two diastereomers; mp 63-68 °C; (Found: C, 68.15; 
H, 6.05; N, 14.65; C32H32N6O2S requires C, 68.06; H, 5.71; N, 
14.88%); m/z (EI) [M+H]+: 565.30 (C32H32N6O2S requires 
564.23); νmax (KBr)/cm-1: 3374, 2924, 1600, 1515 and 1466; δH 
(400 MHz, DMSO-d6) 1.38 [1.37] (3H, d, J = 6.5 Hz, CH3), 
1.70 (1H, m, H3y), 2.00 [2.09] (1H, m, H3x), 2.88 (1H, m, 
H4y), 3.00 (1H, m, H4x), 3.66 (1H, m, H1y), 3.80 (1H, m, 
H1x), 3.83 [3.90] (1H, m, H2), 3.85 (3H, s, OCH3), 4.43 [4.46] 
(1H, qd, J = 6.5, 6.2 Hz, NH-CH), 4.91 [4.95] (1H, d, J = 5.8 
Hz, OH), 6.09 [6.12] (1H, dd, J = 8.6, 2.0 Hz, H3’’), 6.19 
[6.21] (1H, d, J = 6.2 Hz, NH), 6.27 (1H, d, J = 2.0 Hz, H1’’), 
6.71 (1H, d, J = 8.6 Hz, H4’’), 6.86 (1H, dd, J = 7.8, 7.5 Hz, 
H7’’), 7.00 (1H, d, J = 7.8 Hz, H9’’), 7.05 (1H, d, J = 7.8 Hz, 
H6’’), 7.11 (1H, dd, J = 7.8, 7.5 Hz, H8’’), 7.15 (1H, m, 
H4’’’), 7.16 (2H, m, H3’ + H5’), 7.27 (2H, m, H3’’’ + H5’’’), 
7.35 (2H, m, H2’’’ + H6’’’), 7.90 (2H, m, H2’ + H6’); δC (100 
MHz, DMSO-d6) 21.0 (C4), 24.5 [24.6] (CH3), 33.0 (C3), 52.2 
[52.1] (HN-CH), 52.7 (C1), 55.6 (OCH3), 65.4 [65.3] (C2), 
101.7 [101.5] (C1’’), 107.4 [107.6] (C3’’), 108.8 (C4a’’), 
115.0 (C3’ + C5’), 115.9 (C9’’), 121.3 (C2’ + C6’), 122.0 
(C7’’), 125.6 (C5a’’), 125.8 (C2’’’ + C6’’’), 126.4 (C4’’’), 
126.9 (C6’’ + C8’’), 127.3 (C4’’), 128.3 (C3’’’ + C5’’’), 129.6 
(C1’), 145.3 (C9a’’), 146.0 (C1’’’), 146.1 (C10a’’), 148.1 
(C2’’), 160.1 (C4’), 166.5 (Ctetrazole). 
 
1-[2-(Butylamino)-10H-phenothiazin-10-yl]-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (3e) 
According to route „C”, this compound was obtained from 
N-butyl-10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-2-
amine (9e, 95 mg) as amorphous solid, 32 mg (49%); mp 114-
115 °C; (Found: C, 65.01; H, 6.39; N, 15.93; C28H32N6O2S 
requires C, 65.09; H, 6.24; N, 16.27%); m/z (EI) [M+H]+: 
517.50 (C28H32N6O2S requires 516.23); νmax (KBr)/cm-1: 3403, 
2956, 1601, 1517 and 1466; δH (300 MHz, CDCl3) 0.94 (3H, t, 
J = 7.2 Hz), 1.36 (2H, m), 1.56 (2H, m), 2.13 (1H, m), 2.20 
(1H, m), 2.86 (1H, br. s), 3.02-3.26 (5H, m), 3.81 (1H, m), 
3.84 (3H, s), 4.04 (1H, dd, J = 13.2, 3.0 Hz), 4.19 (1H, m), 
6.22-6.24 (2H, m), 6.89-7.19 (7H, m), 7.97 (2H, m); δC (75 
MHz, CDCl3) 13.9, 20.2, 21.9, 31.5, 32.2, 43.8, 53.7, 55.6, 
66.4, 101.7, 107.6, 112.8, 114.6 (2C), 116.1, 121.3 (2C), 122.8, 
126.9, 127.6, 128.0, 128.2, 130.4, 145.5, 146.6, 148.7, 160.4, 
166.4. 
 
1-[2-(Diethylamino)-10H-phenothiazin-10-yl]-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (3f) 
According to route „A”, this compound was obtained from 
N,N-diethyl-10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]buta-1,3-dien-1-yl}-10H-phenothiazin-2-amine (2f, 2.0 g) 
as white amorphous solid, 0.48 g (23%). 
According to route „C”, this compound was obtained from 
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-N,N-diethyl-10H-
phenothiazin-2-amine (9f, 0.11 g, 0.14 mmol) as white 
amorphous solid, 0.14 g (86%); mp 51-53 °C; HPLC: using the 
eluent n-hexane:2-propanol + 0.1% diethylamine = 70:30, 
retention times: 9.5 min, 22.1 min; (Found: C, 65.01; H, 6.23; 
N, 15.90; C28H32N6O2S requires C, 65.09; H, 6.24; N, 16.27%); 
m/z (EI) [M+H]+: 517.50 (C28H32N6O2S requires 516.23); νmax 
(KBr)/cm-1: 2967, 2929, 1598, 1516 and 1467; δH (400 MHz, 
DMSO-d6) 1.03 (6H, t, J = 7.1 Hz, N(CH2)2(CH3)2), 1.76 (1H, 
dddd, J = 13.5, 9.3, 8.2, 5.4 Hz, H3y), 2.12 (1H, m, H3x), 2.94 
 (1H, ddd, J = 15.3, 8.2, 7.4 Hz, H4y), 3.03 (1H, ddd, J = 15.3, 
9.1, 5.4 Hz, H4x), 3.28 (4H, q, J = 7.1 Hz, N(CH2)2(CH3)2), 
3.79 (1H, m, H1y), 3.83 (3H, s, OCH3), 3.96 (1H, m, H1x), 
4.00 (1H, m, H2), 5.02 (1H, d, J = 5.4 Hz, OH), 6.27 (1H, m, 
H3’’), 6.29 (1H, m, H1’’), 6.86 (1H, d, J = 8.0 Hz, H4’’), 6.88 
(1H, t, J = 7.5 Hz, H7’’), 7.05 (1H, d, J = 7.5 Hz, H9’’), 7.10 
(1H, d, J = 7.5 Hz, H6’’), 7.14 (1H, m, H8’’), 7.16 (2H, m, H3’ 
+ H5’), 7.88 (2H, m, H2’ + H6’); δC (100 MHz, DMSO-d6) 
12.4 (N(CH2)2(CH3)2, 2C), 21.0 (C4), 33.1 (C3), 43.8 
(N(CH2)2(CH3)2, 2C), 53.0 (C1), 55.6 (OCH3), 65.6 (C2), 
100.5 (C1’’), 106.5 (C3’’), 108.5 (C4a’’), 114.9 (C3’ + C5’), 
116.1 (C9’’), 121.3 (C2’ + C6’), 122.1 (C7’’), 125.8 (C5a’’), 
126.9 (C6’’ + C8’’), 127.6 (C4’’), 129.6 (C1’), 145.4 (C9a’’), 
146.4 (C10a’’), 147.5 (C2’’), 160.0 (C4’), 166.4 (Ctetrazole). 
 
1-[2-(Diphenylamino)-10H-phenothiazin-10-yl]-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (3g) 
According to route „A”, this compound was obtained from 
10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]buta-
1,3-dien-1-yl}-N,N-diphenyl-10H-phenothiazin-2-amine (2g, 
2.38 g) as beige amorphous solid, 1.20 g (49%); mp 70-74 °C, 
(Found: C, 70.51; H, 5.37; N, 13.55; C36H32N6O2S requires C, 
70.57; H, 5.26; N, 13.72%); HRMS cald for C36H32N6O2S 
612.2307 found: 612.2289; m/z: 612 (23%), 584 (62), 569 (3), 
488 (7), 463 (42), 436 (2), 408 (2), 379 (100), 365 (42), 347 
(28), 332 (19), 304 (5), 292 (9), 269 (14), 255 (12), 239 (5), 
225 (9), 210 (13), 186 (6), 167 (12), 136 (4), 122 (38), 108 
(22), 91 (15), 77 (23), 63 (5) and 51 (9); νmax (KBr)/cm-1: 2929, 
1580, 1516, 1456 and 1256; δH (400 MHz, DMSO-d6) 1.69 
(1H, m), 2.00 (1H, m), 2.88 (1H, m), 2.98 (1H, m), 3.61 (1H, 
dd, J = 13.5, 6.2 Hz), 3.74 (1H, dd, J = 13.5, 5.6 Hz), 3.83 (1H, 
m), 3.84 (3H, s), 4.94 (1H, d, J = 5.7 Hz), 6.53-6.56 (2H, m), 
6.93-7.03 (9H, m), 7.14-7.26 (8H, m), 7.89 (2H, m); δC (100 
MHz, DMSO-d6) 21.0, 32.9, 52.9, 55.6, 65.3, 112.0, 115.0 
(2C), 116.3, 118.0, 118.2, 121.2 (2C), 122.6 (2C), 122.9, 123.6 
(4C), 124.5, 127.1, 127.4, 127.8, 129.4 (4C), 129.6, 145.0, 
146.0, 147.0 (2C), 147.1, 160.1, 166.4. 
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-
morpholin-4-yl-10H-phenothiazin-10-yl)butan-2-ol (3h) 
According to route „A”, this compound was obtained from 
10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]buta-
1,3-dien-1-yl}-2-morpholin-4-yl-10H-phenothiazine (2h, 2.05 
g, 0.49 mmol) as white crystals, 0.70 g (33%). 
According to route „C”, this compound was obtained from 
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-morpholin-4-yl-
10H-phenothiazine (9h, 0.11 g) as white crystals, 0.14 g 
(87%); mp 64-68 °C; HPLC: using the eluent n-hexane:2-
propanol + 0.1% diethylamine = 70:30, retention times: 11.8 
min, 17.4 min; (Found: C, 63.37; H, 5.80; N, 15.48; 
C28H30N6O3S requires C, 63.38; H, 5.70; N, 15.84%); m/z (EI) 
[M+H]+: 531.40 (C28H30N6O3S requires 530.21); νmax 
(KBr)/cm-1: 3307, 2959, 1596, 1516 and 1466; δH (300 MHz, 
CDCl3) 2.06 (1H, m), 2.21 (1H, m), 2.77 (1H, br. s), 3.09-3.18 
(6H, m), 3.83-4.19 (6H, m), 3.89 (3H, s), 3.95 (1H, br. s), 6.45-
6.58 (2H, m), 6.91-7.20 (7H, m), 7.97 (2H, m); δC (75 MHz, 
CDCl3) 22.0, 32.4, 49.9 (2C), 54.2, 55.9, 66.6, 67.0 (2C), 
105.1, 111.2, 114.9 (2C), 116.5, 117.2, 121.5 (2C), 123.3, 
127.4, 127.7, 127.9, 128.3, 130.6, 145.6, 146.7, 151.7, 160.6, 
166.6. 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-[2-(4-
methylpiperazin-1-yl)-10H-phenothiazin-10-yl]butan-2-ol 
(3i) 
According to route „A”, this compound was obtained from 
10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]buta-
1,3-dien-1-yl}-2-(4-methylpiperazin-1-yl)-10H-phenothiazine 
(2i, 2.01 g) as a brown oil, 1.06 g (49%). 
According to route „B”, this compound was obtained from 
10-{2-(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butyl}-2-(4-methylpiperazin-1-yl)-10H-phenothiazine (7i, 
0.32 g, 0.50 mmol) as a brown oil, 0.09 g (33%). 
According to route „C”, this compound was obtained from 
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-(4-methylpiperazin-
1-yl)-10H-phenothiazine (9i, 51 mg) as a brown oil, 47 mg 
(64%); HPLC: using the eluent n-hexane:2-propanol + 0.1% 
diethylamine = 70:30, retention times: 17.3 min, 23.8 min; 
(Found: C, 64.06; H, 6.18; N, 17.91; C29H33N7O2S requires C, 
64.06; H, 6.12; N, 18.03%); HRMS calcd for C29H33N7O2S 
543.2416 found: 543.2434; m/z: 543 (54%), 515 (70), 464 (26), 
394 (47), 310 (83), 239 (29), 207 (38), 167 (18), 108 (56) and 
70 (87); νmax (film)/cm-1: 2966, 2843, 1594, 1514 and 1257; δH 
(300 MHz, CDCl3) 2.06 (1H, m), 2.26 (1H, m), 2.34 (3H, s), 
2.54 (4H, t, J = 5.1 Hz), 2.80 (1H, br. s), 3.10-3.24 (6H, m), 
3.87 (1H, m), 3.88 (3H, s), 4.07 (1H, dd, J = 13.5, 3.6 Hz), 
4.20 (1H, m), 6.52-6.56 (2H, m), 6.90-7.20 (7H, m), 7.98 (2H, 
m); δC (75 MHz, CDCl3) 22.1, 32.4, 46.3, 49.6 (2C), 54.2, 55.2 
(2C),, 55.9, 66.7, 105.4, 111.5, 114.9 (2C), 116.5, 116.7, 121.6 
(2C), 123.2, 127.3, 127.9, 128.0, 128.2, 130.9, 145.6, 146.7, 
151.8, 160.6, 166.6. 
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-
piperidin-1-yl-10H-phenothiazin-10-yl)butan-2-ol (3j) 
According to route „A”, this compound was obtained from 
10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]buta-
1,3-dien-1-yl}-2-piperidin-1-yl-10H-phenothiazin (2j, 2.0 g) as 
beige amorphous solid, 0.91 g (44%); mp 63-67 °C; (Found: C, 
65.81; H, 6.31; N, 15.50; C29H32N6O2S requires C, 65.88; H, 
6.10; N, 15.90%); HRMS calcd for C29H32N6O2S 528.2307 
found: 528.2314; m/z: 528 (79%), 500 (50), 485 (2), 379 (22), 
346 (17), 307 (4), 295 (100), 281 (95), 263 (29), 225 (11), 205 
(16), 179 (5), 137 (4), 122 (30), 106 (11), 92 (4), 80 (10) and 
65 (4); νmax (KBr)/cm-1: 2931, 1595, 1516, 1464 and 1256; δH 
(300 MHz, CDCl3) 1.56 (2H, m), 1.68 (4H, m), 2.05 (1H, m), 
2.24 (1H, m), 2.78 (1H, br. s), 3.06-3.25 (6H, m), 3.84 (1H, 
m), 3.86 (3H, s), 4.04-4.21 (2H, m), 6.52-6.57 (2H, m), 6.93-
7.20 (7H, m), 7.99 (2H, m); δC (75 MHz, CDCl3) 21.9, 24.9, 
25.8 (2C), 32.2, 51.0 (2C), 53.8, 55.6, 66.4, 105.6, 111.8, 114.6 
(2C), 115.8, 116.2, 121.3 (2C), 122.9, 127.0, 127.7, 127.8, 
127.9, 132.0, 145.4, 146.3, 152.5, 160.4, 166.4. 
 
4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-
pyrrolidin-1-yl-10H-phenothiazin-10-yl)butan-2-ol (3k) 
According to route „B”, this compound was obtained from 
10-{2-(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butyl}-2-pyrrolidin-1-yl-10H-phenothiazine (7k, 50 mg) as 
brown amorphous solid, 26 mg (62%); mp 154-157 °C; 
(Found: C, 64.99; H, 6.01; N, 15.93; C28H30N6O2S requires C, 
65.35; H, 5.88; N, 16.33%), m/z (EI) [M+Na]+: 536.30 
(C28H30N6O2S requires 514.64); νmax (KBr)/cm-1: 3345, 2852, 
1598, 1515 and 1257; δH (300 MHz, CDCl3) 1.96-2.09 (5H, m), 
 2.21 (1H, m), 2.85 (1H, br. s), 3.13-3.22 (6H, m), 3.88 (3H, s), 
3.91 (1H, m), 4.09 (1H, dd, J = 13.5, 3.3 Hz), 4.23 (1H, m), 
6.14-6.21 (2H, m), 6.89-7.29 (7H, m), 7.98 (2H, m); δC (75 
MHz, CDCl3) 22.1, 25.6 (2C), 32.4, 48.0 (2C), 54.1, 55.9, 
66.7, 100.8, 107.3, 111.4, 114.8 (2C), 116.4, 121.5 (2C), 123.0, 
127.1, 127.8, 128.3, 128.5, 130.7, 145.9, 146.9, 148.3, 160.6, 
166.7. 
 
N-(10-{2-Hydroxy-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]butyl}-10H-phenothiazin-2-yl)formamide (3l) (E/Z 
isomers) 
According to route „C”, this compound was obtained from 
N-[10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-2-
yl]formamide (9l, 0.10 g, 0.14 mmol) as grey amorphous solid, 
0.06 g (99%); mp 75-78 °C; (Found: C, 61.16; H, 4.61; N, 
17.02; C25H24N6O3S requires C, 61.46; H, 4.95; N, 17.20%); 
m/z (EI) [M+H]+: 489.20 (C25H24N6O3S requires 488.16); νmax 
(KBr)/cm-1: 3266, 1685, 1591, 1515 and 1461; δH (300 MHz, 
CDCl3) 2.07 (1H, m), 2.21 (1H, m), 2.84 (1H, br. s), 3.16 (2H, 
m), 3.86 (3H, s), 3.88 (1H, m), 4.07 (1H, m), 4.17 (1H, m), 
6.67 [6.70] (1H, s), 6.91-7.58 (9H, m), 7.96 (2H, m), 8.33 
[8.64] (1H, d, J = 1.1, [J = 11.0] Hz); δC (75 MHz, CDCl3) 
22.1, 32.5, 54.1, 55.9, 66.6, 108.7 [108.0], 114.6 [113.4], 114.9 
(2C), 116.4, 116.5, 121.5 (2C), 123.5, 123.8, 127.7, 127.8, 
128.0, 128.7, 136.9, 145.3 [145.0], 146.0 [146.9], 159.1, 162.3 
[160.7], 166.6 [166.4]. 
 
N-(10-{2-Hydroxy-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]butyl}-10H-phenothiazin-2-yl)acetamide (3m) 
According to route „C”, this compound was obtained from 
N-[10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-2-
yl]acetamide (9m, 0.10 g, 0.14 mmol) as grey amorphous 
solid, 65 mg (96%); mp 99-100 °C; (Found: C, 62.04; H, 4.99; 
N, 16.56; C26H26N6O3S requires C, 62.13; H, 5.21; N, 16.72%); 
m/z (EI) [M+H]+: 503.30 (C26H26N6O3S requires 502.18); 
νmax(KBr)/cm-1: 3306, 2934, 1666, 1515 and 1462; δH (400 
MHz, DMSO-d6) 1.77 (1H, dddd, J = 14.1, 9.0, 8.4, 5.4 Hz, 
H3y), 2.00 (3H, s, CH3), 2.12 (1H, m, H3x), 2.94 (1H, ddd, J = 
14.8, 8.4, 7.4 Hz, H4y), 3.05 (1H, ddd, J = 14.8, 8.4, 5.4 Hz, 
H4x), 3.77 (1H, dd, J = 13.6, 6.5 Hz, H1y), 3.84 (3H, s, 
OCH3), 3.92 (1H, dd, J = 13.6, 5.8 Hz, H1x), 4.00 (1H, m, 
H2), 5.04 (1H, d, J = 5.5 Hz, OH), 6.92 (1H, m, H7’’), 7.03 
(1H, d, J = 8.0 Hz, H4’’), 7.08 (1H, d, J = 8.1 Hz, H9’’), 7.12 
(1H, dd, J = 7.8, 1.3 Hz, H6’’), 7.15-7.16 (4H, m, H3’ + H5’ + 
H3’’ + H8’’), 7.40 (1H, d, J = 1.3 Hz, H1’’), 7.87 (2H, m, H2’ 
+ H6’), 9.90 (1H, s, NH); δC (100 MHz, DMSO-d6) 20.9 (C4), 
23.9 (O=C-CH3), 33.0 (C3), 52.9 (C1), 55.6 (OCH3), 65.3 
(C2), 107.1 (C1’’), 113.2 (C3’’), 115.0 (C3’ + C5’), 116.2 
(C9’’), 117.6 (C2’’), 121.3 (C2’ + C6’), 122.6 (C7’’), 124.6 
(C5a’’), 127.0 (C6’’), 127.1 (C4’’), 127.3 (C8’’), 129.6 (C1’), 
139.2 (C4a’’), 144.9 (C9a’’), 145.5 (C10a’’), 160.0 (C4’), 
166.4 (Ctetrazole), 168.3 (O=C-CH3). 
 
1-[2-(Diethylamino)-5-oxido-10H-phenothiazin-10-yl]-4-
[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (4f) 
This compound was obtained from the hydroboration-
oxidation of N,N-diethyl-10-{(1E,3Z)-4-[2-(4-methoxyphenyl)-
2H-tetrazol-5-yl]buta-1,3-dien-1-yl}-10H-phenothiazin-2-
amine13a (2f, 0.21 g, 0.42 mmol) as yellow amorphous solid; 
0.15 g (67%); the mixture of two diastereomers; mp 76-80 °C; 
(Found: C, 63.01; H, 5.90; N, 15.66; C28H32N6O3S requires C, 
63.14; H, 6.06; N, 15.78%); m/z (EI) [M-N2]+: 504.00 
(C28H32N6O3S requires 532.23); νmax (KBr)/cm-1: 3301, 2968, 
1590, 1516 and 1466; δH (400 MHz, DMSO-d6) 1.12 (6H, m, 
N(CH2)2(CH3)2), 1.84 (1H, m, H3y), 2.06 (1H, m, H3x), 2.98 
(1H, m, H4y), 3.03 (1H, m, H4x), 3.43 (4H, m, 
N(CH2)2(CH3)2), 3.86 (3H, s, OCH3), 4.07 (1H, m, H2), 4.30 
(1H, m, H1y), 4.44 (1H, m, H1x), 5.00 (1H, br. s, OH), 6.58 
(1H, m, H3’’), 6.89 [6.56] (1H, m, H1’’), 7.16 (2H, m, H3’ + 
H5’), 7.19 (1H, m, H9’’), 7.57 (1H, m, H7’’), 7.60 (1H, m, 
H8’’), 7.61 [7.87] (1H, m, H4’’), 7.81 (1H, m, H6’’), 7.93 (2H, 
m, H2’ + H6’); δC (100 MHz, DMSO-d6) 12.3 (N(CH2)2(CH3)2, 
2C), 21.1 (C4), 32.3 (C3), 44.0 (N(CH2)2(CH3)2, 2C), 54.4 
[54.3] (C1), 55.6 (OCH3), 67.4 [67.2] (C2), 98.9 [97.9] (C1’’), 
106.3 [106.4] (C3’’), 113.1 [113.0] (C4a’’), 115.0 (C3’ + C5’), 
117.8 [118.6] (C4’’), 121.2 (C9’’), 121.3 (C2’ + C6’), 126.6 
[126.8] (C5a’’), 129.6 (C6’’), 129.7 (C1’), 131.7 (C7’’), 131.8 
(C8’’), 140.0 [139.0] (C9a’’), 141.7 [140.7] (C10a’’), 150.7 
(C2’’), 160.1 (C4’), 166.4 (Ctetrazole). 
 
General procedure for preparation of 1-(2-amino)-5-
oxido-10H-phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-
2H-tetrazol-5-yl]butan-2-ol derivatives (4 and 11) 
A round-bottomed flask was charged with Pd-catalyst: 
Pd2(dba)3 or Pd(OAc)2 (5-7.5 mol%), ligand: XPhos (10-15 
mol%), 1-(2-chloro-5-oxido-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol12 (10), secondary 
amine, base: NaOtBu or Cs2CO3, and dry toluene (5 mL). The 
flask was flushed with argon for 5 min. The resulting mixture 
was heated under reflux with magnetic stirring for 0.5-7 h. 
After cooling down to rt the reaction mixture was concentrated 
and the residue was purified by flash chromatography on silica 
gel using the eluent dichloromethane, then n-hexane:ethyl 
acetate = 2:1 and 1:1 and the crude product was recrystallized 
from methanol to give the final product as yellow-white 
crystals. 
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-
morpholin-4-yl-5-oxido-10H-phenothiazin-10-yl)butan-2-ol 
(4h) 
This compound was obtained from the reaction of 1-(2-
chloro-5-oxido-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (10, 0.30 g, 0.61 
mmol), Pd2(dba)3 (0.03 g, 0.03 mmol, 5 mol%), XPhos (0.03 g, 
0.06 mmol, 10 mol%), NaOtBu (0.12 g, 1.21 mmol), and 
morpholine (0.11 mL, 1.21 mmol). The reaction time was 0.5 
h. After recrystallization, the white-yellow crystals were 
collected by filtration, 0.26 g (78%); mp 88-90 °C; (Found: C, 
61.15; H, 5.64; N, 14.99; C28H30N6O4S requires C, 61.52; H, 
5.53; N, 15.37%); m/z (EI) [M+H]+: 547.40 (C28H30N6O4S 
requires 546.20); νmax (KBr)/cm-1: 3274, 2926, 1589, 1516 and 
1256; δH (400 MHz, DMSO-d6) 1.86 (1H, m, H3y), 2.06 (1H, 
m, H3x), 2.97 (1H, m, H4y), 3.06 (1H, m, H4x), 3.29 (4H, m, 
N-(CH2)2), 3.74 (4H, m, O-(CH2)2), 3.84 (3H, s, OCH3), 4.05 
(1H, m, H2), 4.34 (1H, m, H1y), 4.48 (1H, m, H1x), 5.17 (1H, 
br. s, OH), 6.89 (1H, m, H3’’), 6.97 [7.25] (1H, m, H1’’), 7.16 
(2H, m, H3’ + H5’), 7.22 (1H, m, H7’’), 7.58 [7.61] (1H, m, 
H8’’), 7.70 (1H, m, H4’’), 7.85 (1H, m, H6’’), 7.86 [7.65] (1H, 
m, H9’’), 7.92 (2H, m, H2’ + H6’); δC (100 MHz, DMSO-d6) 
21.0 (C4), 32.0 (C3), 47.4 (N-(CH2)2, 2C), 54.0 [54.2] (C1), 
55.6 (OCH3), 65.9 (O-(CH2)2, 2C), 67.2 [67.3] (C2), 102.0 
[102.7] (C1’’), 109.1 [109.3] (C3’’), 115.0 (C3’ + C5’), 116.5 
 (C4a’’), 118.5 [118.0] (C9’’), 121.3 (C2’ + C6’), 121.5 (C7’’), 
127.2 (C5a’’), 129.6 (C1’), 129.8 (C6’’), 131.1 (C4’’), 132.1 
[132.3] (C8’’), 138.8 (C9a’’), 140.4 (C10a’’), 154.2 (C2’’), 
160.1 (C4’), 166.4 (Ctetrazole). 
The same product was isolated from the reaction of 4-(2-(4-
methoxyphenyl)-2H-tetrazol-5-yl)-1-(2-morpholino-10H-
phenothiazin-10-yl)butan-2-ol (3h, 0.04 g, 0.08 mmol) and m-
CPBA (0.02 g, 0.11 mmol) in abs. dichloromethane (1 mL) to 
give white-yellow crystals, 0.04 g (98%).  
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-[2-(4-
methylpiperazin-1-yl)-5-oxido-10H-phenothiazin-10-
yl]butan-2-ol (4i) 
This compound was obtained from the reaction of Pd(OAc)2 
(0.01 g, 0.05 mmol, 7.5 mol%), XPhos (0.04 g, 0.09 mmol, 15 
mol%), NaOtBu (0.12 g, 1.21 mmol), 1-(2-chloro-5-oxido-
10H-phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]butan-2-ol (10, 0.30 g, 0.61 mmol) and N-methyl-
piperazine (0.14 mL, 1.21 mmol). The reaction time was 0.5 h. 
After recrystallization, the white-yellow crystals were collected 
by filtration, 73 mg (22%); mp 211-214 °C; (Found: C, 62.20; 
H, 5.69; N, 17.21; C29H33N7O3S requires C, 62.23; H, 5.94; N, 
17.52%); m/z (EI) [M+H]+: 560.20 (C29H33N7O3S requires 
559.24); νmax (KBr)/cm-1: 3285, 2950, 1589, 1516 and 1255; δH 
(400 MHz, DMSO-d6) 1.85 (1H, m, H3y), 2.04 (1H, m, H3x), 
2.22 (3H, s, CH3), 2.42 (4H, m, H3C-N-(CH2)2), 3.00 (1H, ddd, 
J = 15.4, 8.6, 7.6 Hz, H4y), 3.06 (1H, ddd, J = 15.4, 9.4. 5.4 
Hz, H4x), 3.34 (4H, m, N-(CH2)2), 3.85 (3H, s, OCH3), 4.03 
(1H, m, H2), 4.36 (1H, dd, J = 14.4, 8.2 Hz, H1y), 4.44 (1H, 
dd, J = 14.4, 3.5 Hz, H1x), 4.86 (1H, d, J = 3.5 Hz, OH), 6.86 
(1H, dd, J = 8.5, 1.3 Hz, H3’’), 6.94 (1H, d, J = 1.3 Hz, H1’’), 
7.18 (2H, m, H3’ + H5’), 7.22 (1H, dd, J = 7.9, 7.1 Hz, H7’’), 
7.59 (1H, ddd, J = 8.4, 7.1, 1.4 Hz, H8’’), 7.67 (1H, d, J = 8.5 
Hz, H4’’), 7.85 (1H, dd, J = 7.9, 1.4, H6’’), 7.86 (1H, d, J = 
8.4 Hz, H9’’), 7.90 (2H, m, H2’ + H6’); δC (100 MHz, DMSO-
d6) 21.0 (C4), 32.0 (C3), 45.7 (CH3), 47.1 (N-(CH2)2, 2C), 54.0 
(C1), 54.3 (H3C-N-(CH2)2, 2C), 55.6 (OCH3), 67.2 (C2), 102.0 
(C1’’), 109.3 (C3’’), 115.0 (C3’ + C5’), 116.0 (C4a’’), 118.6 
(C9’’), 121.3 (C2’ + C6’), 121.6 (C7’’), 127.2 (C5a’’), 129.6 
(C1’), 129.7 (C6’’), 131.1 (C4’’), 132.0 (C8’’), 138.8 (C9a’’), 
141.3 (C10a’’), 154.0 (C2’’), 160.1 (C4’), 166.4 (Ctetrazole). 
 
1-(2-Chloro-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (5) 
This compound was synthesized according to the literature 
procedure12. 
 
10-{2-(Benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]butyl}-2-chloro-10H-phenothiazine (6). 
To a solution of 1-(2-chloro-10H-phenothiazin-10-yl)-4-[2-
(4-methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (5, 0.30 g, 0.63 
mmol) in abs. DMF (5 mL) in a dried, round-bottomed flask 
equipped with a side arm and cooled to 0 °C in an argon 
atmosphere was added sodium hydride (60%, 0.30 g, 7.65 
mmol). The reaction mixture became a suspension. To this 
suspension was added benzyl bromide (0.66 mL, 5.63 mmol) 
dropwise and the starting suspension turned to a clear solution. 
This mixture was then stirred at rt for 2.5 h, then the solvent 
was removed in vacuo. The residue was dissolved in water (20 
mL), and was neutralized by saturated NH4Cl solution. After 
extraction with dichloromethane (3 x 10 mL), the combined 
organic phase was dried over Na2SO4, filtered and evaporated. 
The residue was purified by flash chromatography on silica gel 
using the eluent dichloromethane, then n-hexane:ethyl acetate 
= 4:1. The crude product was recrystallized from n-hexane and 
the white crystals were collected by filtration, 0.27 g (75%); 
mp 114-116 °C; (Found: C, 65.22; H, 4.89; N, 12.11; 
C31H28ClN5O2S requires C, 65.31; H, 4.95; N, 12.28%); νmax 
(KBr)/cm-1: 3410, 2960, 1515, 1454 and 1252; δH (300 MHz, 
CDCl3) 2.11 (1H, m), 2.54 (1H, m), 3.02-3.11 (2H, m), 3.85 
(3H, s), 3.92 (1H, m), 4.07 (2H, m), 4.58 (1H, d, J = 11.1 Hz), 
4.67 (1H, d, J = 11.1 Hz), 6.79-7.30 (14H, m), 7.90 (2H, m); δC 
(75 MHz, CDCl3) 22.4, 31.2, 51.8, 55.8, 72.9, 73.8, 114.7 
(2C), 116.2, 116.3, 121.4 (2C), 122.7, 123.4, 124.5, 125.7, 
127.6, 127.9 (2C), 128.3 (2C), 128.5, 129.3, 130.5, 130.8, 
133.6, 138.3, 144.7, 146.8, 160.5, 166.4. 
 
General procedure for preparation of 10-{2-(benzyloxy)-
4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-10H-
phenothiazine-2-amine/amide derivatives (7) applying 
Buchwald-Hartwig cross-coupling reaction 
A round-bottomed flask was charged with Pd-catalyst: 
Pd2(dba)3 (7.5 mol%), ligand: XPhos (15 mol%), 10-{2-
(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-
2-chloro-10H-phenothiazine (6), the appropriate amine/amide, 
base: NaOtBu or K2CO3, and dry toluene (5 mL). The flask 
was flushed with argon for 5 min. The resulting mixture was 
heated under reflux with magnetic stirring for 1.5-43 h. After 
cooling down to rt the reaction mixture was concentrated and 
the residue was purified by flash column chromatography on 
silica gel using the eluent dichloromethane, then n-
hexane:ethyl acetate = 2:1 and 1:1 to give the final product. 
 
N-benzyl-10-{2-(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl}-10H-phenothiazin-2-amine (7c) 
This compound was obtained from the reaction of 10-{2-
(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-
2-chloro-10H-phenothiazine (6, 0.30 g, 0.52 mmol) and 
benzylamine (0.11 mL, 1.00 mmol) to give the product as 
brown amorphous solid, 0.25 g (67%). The reaction time was 
1.5 h; mp 40-45 °C; (Found: C, 71.28; H, 5.70; N, 13.05; 
C38H36N6O2S requires C, 71.22; H, 5.66; N, 13.11%); HRMS 
calcd for C38H36N6O2S 640.2620 found: 640.2592; m/z: 640 
(2%), 612 (14), 491 (75), 458 (2), 401 (5), 342 (2), 317 (75), 
226 (25), 186 (27), 123 (27) and 91 (100); νmax (KBr)/cm-1: 
2927, 2853, 1515, 1453 and 1256; δH (400 MHz, DMSO-d6) 
1.90 (1H, m, H3y), 2.13 (1H, m, H3x), 2.90 (1H, m, H4y), 2.98 
(1H, m, H4x), 3.85 (3H, s, OCH3), 3.88 (1H, m, H1y), 3.90 
(1H, m, H2), 4.05 (1H, m, H1x), 4.25 (2H, m, NH-CH2), 4.43 
(1H, d, J = 12.0 Hz, O-CH1y), 4.67 (1H, d, J = 12.0 Hz, O-
CH1x), 6.25-6.28 (2H, m, H3’’ + NH), 6.37 (1H, d, J = 2.1 Hz, 
H1’’), 6.83 (1H, d, J = 8.2 Hz, H4’’), 6.90 (1H, dd, J = 7.8, 7.4 
Hz, H7’’), 7.05 (1H, d, J = 8.3 Hz, H9’’), 7.10-7.25 (10H, m, 
H3’ + H5’ + H6’’ + H8’’ + H4’’’ + H2’’’’ + H3’’’’ + H4’’’’ + 
H5’’’’ + H6’’’’), 7.28 (2H, m, H3’’’ + H5’’’), 7.33 (2H, m, 
H2’’’ + H6’’’), 7.90 (2H, m, H2’ + H6’); δC (100 MHz, 
DMSO-d6) 20.7 (C4), 30.5 (C3), 46.5 (NH-CH2), 50.7 (C1), 
55.6 (OCH3), 71.3 (O-CH2), 73.3 (C2), 101.1 (C1’’), 107.2 
(C3’’), 109.1 (C4a’’), 115.0 (C3’ + C5’), 116.2 (C9’’), 121.3 
(C2’ + C6’), 122.2 (C7’’), 126.0 (C5a’’), 126.6 (C4’’’), 127.0 
(C8’’), 127.1 (C2’’’ + C6’’’), 127.3 (C4’’), 127.6 (C6’’ + 
C4’’’’), 127.8 (C2’’’’ + C6’’’’), 128.0 (C3’’’’ + C5’’’’), 128.2 
(C3’’’ + C5’’’), 129.6 (C1’), 138.5 (C1’’’’), 140.0 (C1’’’), 
 145.4 (C10a’’), 146.1 (C9a’’), 148.9 (C2’’), 160.1 (C4’), 166.2 
(Ctetrazole). 
 
10-{2-(Benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]butyl}-N-[(1R)-1-phenylethyl]-10H-phenothiazin-2-
amine (7d) 
This compound was obtained from the reaction of 10-{2-
(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-
2-chloro-10H-phenothiazine (6, 0.30 g, 0.52 mmol) and (R)-
phenylethylamine (0.13 mL, 1.04 mmol) to give the product as 
a brown oil; 0.22 g (64%); a mixture of two diastereomers. The 
reaction time was 1.5 h; (Found: C, 71.67; H, 5.95; N, 12.53; 
C39H38N6O2S requires C, 71.53; H, 5.85; N, 12.83%); HRMS 
calcd for C39H38N6O2S 654.2777 found: 654.2794; m/z: 654 
(79%), 626 (21), 584 (50), 505 (40), 463 (61), 433 (16), 399 
(6), 379 (88), 331 (84), 281 (60), 226 (30), 167 (26), 137 (24) 
and 108 (100); νmax (film)/cm-1: 3408, 2927, 1600, 1515 and 
1454; δH (400 MHz, DMSO-d6) 1.38 [1.39] (3H, d, J = 7.1 Hz, 
CH3), 1.90 (1H, m, H3y), 2.10 (1H, m, H3x), 2.95 (2H, m, H4y 
+ H4x), 3.83 (1H, m, H1y), 3.99 (1H, m, H1x), 3.85 (3H, s, 
OCH3), 3.91 (1H, m, H2), 4.41 (1H, d, J = 11.5 Hz, O-CH1y), 
4.45 (1H, m, HN-CH), 4.64 (1H, d, J = 11.5 Hz, O-CH1x), 
6.16 (1H, dd, J = 8.2, 2.2 Hz, H3’’), 6.21 [6.20] (1H, d, J = 8.5 
Hz, NH), 6.29 (1H, d, J = 2.2 Hz, H1’’), 6.76 (1H, d, J = 8.2 
Hz, H4’’), 6.89 (1H, ddd, J = 8.0, 7.3, 2.2 Hz, H7’’), 7.02 (1H, 
dd, J = 8.6, 1.4 Hz, H9’’), 7.10-7.38 (14H, m, H3’ + H5’ + 
H6’’ + H8’’ + H2’’’ + H3’’’ + H4’’’ + H5’’’ + H6’’’ + H2’’’’ 
+ H3’’’’ + H4’’’’ + H5’’’’ + H6’’’’), 7.90 (2H, m, H2’ + H6’); 
δC (100 MHz, DMSO-d6) 20.6 (C4), 24.6 (CH3), 30.4 (C3), 
50.7 (C1), 52.1 (HN-CH), 55.6 (OCH3), 71.3 (O-CH2), 73.2 
(C2), 101.6 (C1’’), 107.7 (C3’’), 108.9 (C4a’’), 115.0 (C3’ + 
C5’), 116.1 (C9’’), 121.3 (C2’ + C6’), 122.2 (C7’’), 125.7 
(C5a’’), 125.8 (C2’’’ + C6’’’), 125.9 (C4’’’’), 126.4 (C4’’’), 
127.0 (C8’’), 127.3 (C6’’), 127.4 (C4’’), 127.8 (C2’’’’ + 
C6’’’’), 128.0 (C3’’’’ + C5’’’’), 128.3 (C3’’’ + C5’’’), 129.6 
(C1’), 138.5 (C1’’’’), 145.3 (C9a’’), 145.9 (C1’’’), 146.1 
(C10a’’), 148.1 (C2’’), 160.1 (C4’), 166.2 (Ctetrazole). 
 
10-{2-(Benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]butyl}-2-(4-methylpiperazin-1-yl)-10H-phenothiazine 
(7i) 
This compound was obtained from the reaction of 10-{2-
(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-
2-chloro-10H-phenothiazine (6, 0.20 g, 0.35 mmol) and N-
methylpiperazine (0.08 mL, 0.70 mmol) to give the product as 
a brown oil, 0.44 g (99%). The reaction time was 18 h. (Found: 
C, 68,28; H, 6,53; N, 15,20; C36H39N7O2S requires C, 68.22; H, 
6.20; N, 15.47%); m/z (EI) [M+H]+: 634.60 (C36H39N7O2S 
requires 633.29); νmax (film)/cm-1: 3061, 2937, 2839 1583 and 
1515; δH (300 MHz, CDCl3) 2.11 (1H, m), 2.25 (3H, s), 2.28 
(1H, m), 2.53 (4H, t, J = 5.1 Hz), 2.91-3.14 (6H, m), 3.88 (3H, 
s), 3.97 (1H, dd, J = 12.6, 4.8 Hz), 4.05-4.18 (2H, m), 4.60 
(1H, d, J = 11.2 Hz), 4.78 (1H, d, J = 11.2 Hz), 6.48-6.53 (2H, 
m), 6.80-7.26 (12H, m), 7.89-7.94 (2H, m); δC (75 MHz, 
CDCl3) 21.5, 31.4, 43.2, 49.6 (2C), 52.1, 55.3 (2C), 55.9, 72.9, 
74.2, 105.0, 111.2, 114.8 (2C), 116.1, 121.5 (2C), 122.8, 126.0, 
127.1, 127.2, 127.8 (2C), 127.9, 128.0, 128.1 (2C), 128.2, 
128.4, 138.6, 145.4, 146.9, 151.7, 160.5, 166.6. 
 
10-{2-(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-
5-yl]butyl}-2-pyrrolidin-1-yl-10H-phenothiazine (7k) 
This compound was obtained from the reaction of 10-{2-
(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-
2-chloro-10H-phenothiazine (6, 0.30 g, 0.52 mmol) and 
pyrrolidine (0.09 mL, 1.04 mmol) to give the product as beige 
amorphous solid, 0.26 g (80%). The reaction time was 1.5 h; 
mp 43-44 °C; (Found: C, 69.86; H, 6.06; N, 13.81; 
C35H36N6O2S requires C, 69.51; H, 6.00; N, 13.90%): HRMS 
calcd for C35H36N6O2S 604.2620 found: 604.2593; m/z: 604 
(59%), 535 (40), 455 (64), 422 (13), 322 (9), 281 (100), 212 
(94), 180 (29), 138 (11) and 108 (69); νmax (KBr)/cm-1: 2838, 
1599, 1515, 1459 and 1255; δH (300 MHz, DMSO-d6) 1.95 
(4H, t, J = 6.3 Hz), 2.13 (1H, m), 2.31 (1H, m), 3.08 (2H, m), 
3.19 (4H, t, J = 6.3 Hz), 3.88 (3H, s), 4.00 (1H, m), 4.18 (2H, 
m), 4.60 (1H, d, J = 11.2 Hz), 4.80 (1H, d, J = 11.2 Hz),  6.10-
6.18 (2H, m), 6.81-7.29 (12H, m), 7.91 (2H, m); δC (75 MHz, 
DMSO-d6) 21.5, 25.6 (2C), 31.4, 48.0 (2C), 52.0, 55.9, 72.9, 
74.3, 100.4, 106.9, 110.6, 114.8 (2C), 115.9, 121.5 (2C), 122.6, 
127.0, 127.5, 127.7, 127.8, 127.9, 128.3, 128.4 (2C), 128.5 
(2C), 138.7, 145.9, 146.9, 148.2, 160.5, 166.7. 
 
N-(10-{2-(Benzyloxy)-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl}-10H-phenothiazin-2-yl)formamide (7l) 
(E/Z isomers) 
This compound was obtained from the reaction of 10-{2-
(benzyloxy)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl}-
2-chloro-10H-phenothiazine (6, 0.30 g, 0.52 mmol) and 
formamide (0.04 mL, 1.04 mmol) to give the product as beige 
amorphous solid, 87 mg (29%); the mixture of amide rotamers. 
The reaction time was 43 h; mp 63-67 °C; (Found: C, 66.34; H, 
5.49; N, 14.12; C32H30N6O3S requires C, 66.42; H, 5.23; N, 
14.52%); m/z (EI) [M+H]+: 579.30 (C32H30N6O3S requires 
578.21); νmax (KBr)/cm-1: 2930, 2855, 1694, 1591 and 1516; δH 
(400 MHz, DMSO-d6) 1.97 (1H, m, H3y), 2.18 (1H, m, H3x), 
3.00 (2H, m, H4y + H4x), 3.86 (3H, s, OCH3), 3.98 (1H, m, 
H2), 3.99 (1H, m, H1y), 4.16 (1H, m, H1x), 4.52 [4.50] (1H, 
m, O-CHy), 4.73 [4.70] (1H, m, O-CHx), 6.95 [6.93] (1H, m, 
H7’’), 7.08-7.30 (8H, m, H4’’ + H6’’ + H8’’ + H2’’’ + H3’’’ + 
H4’’’ + H5’’’ + H6’’’), 7.12 (1H, m, H9’’), 7.15 (1H, m, 
H3’’), 7.16 (2H, m, H3’ + H5’), 7.51 [7.00] (1H, s, H1’’), 7.86 
(2H, m, H2’ + H6’), 8.2 (8.8) (1H, d, J = 1.1, [J = 11.0] Hz, 
O=C-H), 10.2 (10.1) (1H, d, J = 1.1, [J = 11.0] Hz, NH); δC 
(100 MHz, DMSO-d6) 20.7 (C4), 30.5 (C3), 50.8 (C1), 55.5 
(OCH3), 71.3 (O-CH2), 73.4 (C2), 107.4 [105.8] (C1’’), 111.8 
(C4a’’), 113.5 (C3’’), 115.0 (C3’ + C5’), 116.4 (C9’’), 119.4 
(C4’’), 121.2 (C2’ + C6’), 122.8 [119.4] (C7’’), 127.3 (C8’’ + 
C6’’), 127.4 (C5a’’), 127.5 (C4’’’), 127.7 (C2’’’ + C6’’’), 
128.0 (C3’’’ + C5’’’), 129.6 (C1’), 138.4 [138.1] (C1’’’), 
144.8 [144.7] (C9a’’), 145.4 [145.2] (C10a’’), 146.3 (C2’’), 
160.0 (C4’), 162.6 (C=O), 166.2 (Ctetrazole). 
 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine (8) 
A solution of 1-(2-chloro-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (5, 3.50 g, 7.29 
mmol) in anhydrous dichloromethane (175 mL) in a dried, 
round-bottomed flask equipped with a side arm and cooled to 0 
°C in an argon atmosphere was treated with imidazole (1.49 g, 
21.88 mmol) in small portions. terc-Butyldiphenylchlorosilane 
(7.30 mL, 28.13 mmol) was added dropwise to the mixture, 
which became a suspension. The resulting reaction was 
allowed to warm up to rt and stirred for 4 d. After completion 
of the reaction, the mixture was diluted with dichloromethane 
 (175 mL) and methanol (22 mL). The clear solution was 
washed with water (150 mL), neutralized with saturated 
aqueous NaHCO3, again with water (150 mL) and finally with 
saturated aqueous NaCl solution (150 mL). The organic phase 
was dried over Na2SO4, filtered and concentrated. The crude 
product was purified by column chromatography on silica gel 
using the eluent n-hexane:ethyl acetate = 6:1 and recrystallized 
by n-hexane to give white crystals, 4.71 g (90%); mp 116-118 
°C; HPLC: using the eluent n-hexane:2-propanol + 0.1% 
diethylamine = 98:2, retention times: 12.4 min, 14.4 min; 
(Found: C, 66.86; H, 5.45; N, 9.67; C40H40ClN5O2SSi requires 
C, 66.88; H, 5.61; N, 9.75%); νmax (KBr)/cm-1: 3070, 2931, 
1516, 1456 and 1255; δH (300 MHz, CDCl3) 1.09 (9H, s), 2.13 
(1H, m), 2.25 (1H, m), 3.05 (2H, t, J = 7.8 Hz), 3.80-3.82 (2H, 
m), 3.86 (3H, s), 4.31 (1H, m), 6.14 (1H, m), 6.59 (1H, m), 
6.80-6.83 (3H, m), 6.90-7.00 (4H, m), 7.32-7.45 (6H, m), 7.71-
7.77 (4H, m), 7.87 (2H, m); δC (75 MHz, CDCl3) 19.6, 20.7, 
27.3 (3C), 32.7, 52.0, 55.9, 68.8, 114.7 (2C), 116.1, 116.3, 
121.4 (2C), 122.8, 123.2, 124.5, 125.7, 127.5, 127.8, 128.0 
(2C), 128.1 (2C), 128.3, 130.1, 130.2, 130.8, 133.4 (2C), 
134.0, 136.1 (2C), 136.2 (2C), 144.3, 147.2, 160.4, 166.7. 
 
General procedure for the preparation of the 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-10H-phenothiazin-2-amine/amide 
derivatives (9) applying Buchwald-Hartwig amination 
A round-bottomed flask was charged with Pd-catalyst: 
Pd2(dba)3 or Pd(OAc)2 (10 mol%), ligand: XPhos (20 mol%), 
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine (8), appropriate amine/amide, base: NaOtBu or 
K2CO3), and dry toluene or 1,4-dioxane (5 mL). The flask was 
flushed with argon for 5 min. The resulting mixture was heated 
at reflux with magnetic stirring for 4-31 h. After cooling down 
to rt the reaction mixture was concentrated and the residue was 
purified by flash column chromatography on silica gel using 
the eluent dichloromethane, then n-hexane:ethyl acetate = 2:1 
and 1:1 to give the product. 
 
N'-[10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-
2-yl]-N,N-dimethylethane-1,2-diamine (9a) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.20 g, 
0.28 mmol) and N,N-dimethylethane-1,2-diamine (0.06 mL, 
0.56 mmol) to give the product as brown amorphous solid, 
0.18 g (84%). The reaction time was 4 h; mp 56-58 °C; 
(Found: C, 68.43; H, 6.38; N, 12.53; C44H51N7O2SSi requires 
C, 68.63; H, 6.68; N, 12.73%); m/z (EI) [M+H]+: 770.30 
(C44H51N7O2SSi requires 769.36); νmax (KBr)/cm-1: 3382, 2932, 
1601, 1516 and 1459; δH (300 MHz, CDCl3) 1.08 (9H, s), 2.14 
(1H, m), 2.22 (1H, m), 2.23 (6H, s), 2.52 (2H, t, J = 5.8 Hz), 
2.98-3.07 (4H, m), 3.81-3.84 (2H, m), 3.86 (3H, s), 4.10 (1H, 
m), 4.36 (1H, m), 5.86 (1H, d, J = 1.8 Hz), 6.10-6.17 (2H, m), 
6.75-6.84 (3H, m), 6.97-7.03 (3H, m), 7.35-7.47 (6H, m), 7.72-
7.80 (4H, m), 7.90 (2H, m); δC (75 MHz, CDCl3) 19.6, 20.7, 
27.3 (3C), 32.6, 41.4, 45.4 (2C), 51.8, 55.8, 58.2, 69.0, 101.7, 
107.2, 112.5, 114.7 (2C), 115.7, 121.5 (2C), 122.4, 126.9, 
127.3, 127.5, 127.9 (2C), 128.0 (2C), 128.3, 130.0, 130.1, 
130.8, 133.6, 134.5, 136.2 (2C), 136.3 (2C), 145.1, 147.2, 
148.8, 160.4, 166.9. 
 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-N-(2-morpholin-4-
ylethyl)-10H-phenothiazin-2-amine (9b) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.10 g, 
0.14 mmol) and 2-morpholinoethanamine (0.04 mL, 0.27 
mmol) to give the product as white amorphous solid, 0.17 g 
(78%). The reaction time was 31 h; mp 64-67 °C; (Found: C, 
67.90; H, 6.98; N, 11.97; C46H53N7O3SSi requires C, 68.03; H, 
6.58; N, 12.07%); m/z (EI) [M+H]+: 812.60 (C46H53N7O3SSi 
requires 811.37); νmax (KBr)/cm-1: 2957, 2855, 1601, 1516 and 
1460; δH (300 MHz, CDCl3) 1.08 (9H, s), 2.15 (1H, m), 2.25 
(1H, m), 2.48 (4H, t, J = 3.9 Hz), 2.60 (2H, t, J = 5.4 Hz), 2.95-
3.15 (4H, m), 3.74 (4H, t, J = 3.9 Hz), 3.82 (2H, m), 3.85 (3H, 
s), 4.10 (1H, br. s), 4.36 (1H, m), 5.87 (1H, d, J = 1.8 Hz), 
6.10-6.17 (2H, m), 6.76-6.85 (3H, m), 7.00-7.03 (3H, m), 7.33-
7.47 (6H, m), 7.73-7.88 (6H, m); δC (75 MHz, CDCl3) 19.6, 
20.7, 27.3 (3C), 32.6, 40.2, 51.8, 53.6 (2C), 55.9, 57.4, 67.2 
(2C), 69.0, 101.6, 107.3, 112.8, 114.7 (2C), 115.7, 121.4 (2C), 
122.5, 126.9, 127.2, 127.5, 127.9 (2C), 128.0 (2C), 128.3, 
130.0, 130.1, 130.8, 133.5, 134.6, 136.2 (2C), 136.3 (2C), 
145.1, 147.3, 148.5, 160.4, 166.9. 
 
N-Butyl-10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-
2-amine (9e) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.20 g, 
0.28 mmol) and n-butylamine (0.06 mL, 0.56 mmol) to give 
the product as beige amorphous solid, 0.12 g (57%). The 
reaction time was 21 h; mp 46-50 °C; (Found: C, 70.38; H, 
6.79; N, 10.83; C44H50N6O2SSi requires C, 69.99; H, 6.67; N, 
11.13%); m/z (EI) [M+H]+: 755.40 (C44H50N6O2SSi requires 
754.35); νmax (KBr)/cm-1: 3408, 2957, 1601, 1516 and 1460; δH 
(300 MHz, CDCl3) 0.97 (3H, t, J = 7.2 Hz), 1.08 (9H, s), 1.40 
(2H, m), 1.55 (2H, m), 2.13 (1H, m), 2.23 (1H, m), 2.95-3.06 
(4H, m), 3.26 (1H, br. s), 3.83 (2H, m), 3,85 (3H, s), 4.35 (1H, 
m), 5.74 (1H, s), 6.09-6.18 (2H, m), 6.74-6.84 (3H, m), 7.00-
7.03 (3H, m), 7.32-7.48 (6H, m), 7.73-7.89 (6H, m); δC (75 
MHz, CDCl3) 13.9, 19.4, 20.3, 20.5, 27.0 (3C), 31.6, 32.3, 
43.7, 51.6, 55.6, 68.6, 101.4, 106.5, 112.0, 114.4 (2C), 115.4, 
121.2 (2C), 122.2, 126.7, 127.0, 127.3, 127.6 (2C), 127.8 (2C), 
128.0, 129.7, 129.8, 130.5, 133.2, 134.3, 136.0 (2C), 136.1 
(2C), 145.0, 146.7, 148.3, 160.1, 166.6. 
 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-N,N-diethyl-10H-
phenothiazin-2-amine (9f) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 1.00 g, 
1.39 mmol) and diethylamine (0.17 mL, 2.79 mmol) to give 
the product as white amorphous solid, 0.92 g (87%). The 
reaction time was 4 h; mp 56-57 °C; HPLC: using the eluent n-
hexane:2-propanol + 0.1% diethylamine = 75:25, retention 
times: 9.6 min, 10.2 min; (Found: C, 69.68; H, 6.68; N, 10.75; 
C44H50N6O2SSi requires C, 69.99; H, 6.67; N, 11.13%); m/z 
(EI) [M+H]+: 755.50 (C44H50N6O2SSi requires 754.35); νmax 
(KBr)/cm-1: 2964, 2856, 1598, 1516 and 1466; δH (300 MHz, 
 CDCl3) 1.07 (9H, s), 1.09 (6H, t, J = 6.9 Hz), 2.13 (1H, m), 
2.27 (1H, m), 3.07 (2H, t, J = 7.2 Hz), 3.23 (4H, q, J = 6.9 Hz), 
3.86 (2H, m), 3.88 (3H, s), 4.36 (1H, m), 5.91 (1H, d, J = 8.4 
Hz), 6.06 (1H, d, J = 2.4 Hz), 6.23 (1H, dd, J = 8.4, 2.7 Hz), 
6.67-6.75 (2H, m), 6.85 (1H, d, J = 8.7 Hz), 6.98-7.00 (3H, m), 
7.32-7.45 (6H, m), 7.73-7.79 (4H, m), 7.88 (2H, m); δC (75 
MHz, CDCl3) 12.8 (2C), 19.6, 20.9, 27.2 (3C), 32.7, 44.8 (2C), 
52.2, 55.9, 69.2, 100.8, 107.4, 111.0, 114.7 (2C), 115.8, 121.4 
(2C), 122.3, 126.8, 127.3, 127.5, 127.9 (2C), 128.0 (2C), 
128.2, 129.9, 130.1, 130.8, 133.4, 134.6, 136.1 (2C), 136.3 
(2C), 144.8, 147.8, 148.2, 160.4, 166.9. 
 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-morpholin-4-yl-
10H-phenothiazine (9h) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.60 g, 
0.83 mmol) and morpholine (0.15 mL, 1.67 mmol) to give the 
product as white amorphous solid, 0.59 g (91%). The reaction 
time was 18 h; mp 63-66 °C; HPLC: using the eluent n-
hexane:2-propanol + 0.1% diethylamine = 75:25, retention 
times: 18.6 min, 19.5 min; (Found: C, 68.98; H, 6.52; N, 
10.53; C44H48N6O3SSi requires C, 68.72; H, 6.29; N, 10.93%); 
m/z (EI) [M+H]+: 769.60 (C44H48N6O3SSi requires 768.33); 
νmax (KBr)/cm-1: 2958, 2855, 1595, 1516 and 1461; δH (300 
MHz, CDCl3 + DMSO-d6) 1.06 (9H, s), 2.08 (1H, m), 2.22 
(1H, m), 2.92-3.03 (6H, m), 3.77 (4H, t, J = 4.8 Hz), 3.85 (2H, 
m), 3.87 (3H, s), 4.31 (1H, m), 6.09 (1H, m), 6.24 (1H, d, J = 
2.1 Hz), 6.44 (1H, dd, J = 8.4, 2.1 Hz), 6.76-6.79 (2H, m), 6.89 
(1H, d, J = 8.4 Hz), 6.96-7.05 (3H, m), 7.30-7.46 (6H, m), 
7.69-7.77 (4H, m), 7.83 (2H, m); δC (75 MHz, CDCl3 + 
DMSO-d6) 12.8, 24.3, 32.0 (3C), 37.4, 54.3 (2C), 56.8, 60.7, 
71.6 (2C), 73.6, 103.1, 109.4, 113.7 (2C), 114.6, 114.8, 120.3 
(2C), 121.6, 125.4, 126.1, 126.5, 126.8 (2C), 126.9 (2C), 
128.9, 129.1, 129.4, 132.0, 133.2, 134.9 (2C), 135.0 (2C), 
143.6, 145.8, 150.5 (2C), 159.4, 165.5. 
 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-(4-
methylpiperazin-1-yl)-10H-phenothiazine (9i) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.60 g, 
0.83 mmol) and N-methylpiperazine (0.19 mL, 1.67 mmol) to 
give the product as beige amorphous solid, 0.48 g (73%). The 
reaction time was 18 h; mp 58-60 °C; HPLC: using the eluent 
n-hexane:2-propanol + 0.1% diethylamine = 75:25, retention 
times: 20.5 min, 23.5 min; (Found: C, 68.79; H, 6.63; N, 
12.24; C45H51N7O2SSi requires C, 69.11; H, 6.57; N, 12.54%); 
m/z (EI) [M+H]+: 782.30 (C45H51N7O2SSi requires 781.36); νmax (KBr)/cm-1: 2932, 2855, 1596, 1516 and 1461; δH (300 
MHz, CDCl3) 1.07 (9H, s), 2.11 (1H, m), 2.28 (1H, m), 2.36 
(3H, s), 2.53 (4H, t, J = 4.8 Hz), 3.02-3.07 (6H, m), 3.83 (2H, 
m), 3.85 (3H, s), 4.34 (1H, m), 5.99 (1H, m), 6.27 (1H, d, J = 
2.1 Hz), 6.44 (1H, dd, J = 8.4, 2.1 Hz), 6.73-6.77 (2H, m), 6.90 
(1H, d, J = 8.4 Hz), 6.96-7.01 (3H, m), 7.31-7.45 (6H, m), 
7.73-7.79 (4H, m), 7.86 (2H, m); δC (75 MHz, CDCl3) 19.6, 
20.8, 27.2 (3C), 32.7, 46.4, 49.5 (2C), 52.1, 55.3 (2C), 55.9, 
69.1, 104.8, 110.8, 114.7 (2C), 115.9, 116.0, 121.5 (2C), 122.6, 
126.9, 127.0, 127.6, 127.9 (2C), 128.1 (2C), 129.9, 130.2, 
130.8, 133.3, 134.6, 136.1 (2C), 136.3 (2C), 144.7, 147.3, 
151.6 (2C), 160.4, 166.9. 
 
N-[10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-
2-yl]formamide (9l) (E/Z isomers) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.20 g, 
0.28 mmol) and formamide (0.02 mL, 0.56 mmol) to give the 
product as beige amorphous solid, 0.14 g (67%). The reaction 
time was 22 h; mp 68-71 °C; (Found: C, 67.36; H, 5.85; N, 
11.37; C41H42N6O3SSi requires C, 67.74; H, 5.82; N, 11.56%); 
m/z (EI) [M+H]+: 727.50 (C41H42N6O3SSi requires 726.28); νmax (KBr)/cm-1: 3309, 2930, 2856, 1697 and 1561; δH (300 
MHz, DMSO-d6) 0.95 (9H, s), 2.05 (2H, m), 2.96 (2H, m), 
3.84 (3H, s), 3.94 (2H, m), 4.19 (1H, m), 6.35 [6.40] (1H, d, J 
= 8.1 Hz), 6.84-6.87 (2H, m), 7.03 (2H, m), 7.10-7.15 (3H, m), 
7.29-7.40 (7H, m), 7.57-7.59 (4H, m), 7.78 (2H, m), 8.24 
[8.72] (1H, d, J = 1.1, [J = 11.0] Hz, O=C-H), 10.1 [10.0] (1H, 
d, J = 1.1, [J = 11.0] Hz, NH); δC (75 MHz, DMSO-d6) 18.8, 
19.9, 26.8 (3C), 32.2, 51.5, 55.6, 68.6, 107.1, 113.5, 114.9 
(2C), 115.7, 118.7, 121.1 (2C), 122.7, 124.8, 127.2 (2C), 
127.3, 127.6 (2C), 127.7 (2C), 129.6, 129.7, 129.9, 132.8 (2C), 
135.3 (2C), 135.4 (2C), 138.1, 143.9, 145.9, 159.6, 160.0, 
165.9. 
 
N-[10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-
2-yl]acetamide (9m) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.20 g, 
0.28 mmol) and acetamide (0.03 g, 0.56 mmol) to give the 
product as beige amorphous solid, 0.09 g (44%). The reaction 
time was 22 h; mp 73-76 °C; (Found: C, 68.04; H, 5.69; N, 
11.16; C42H44N6O3SSi requires C, 68.08; H, 5.99; N, 11.34%); 
m/z (EI) [M+H]+: 741.70 (C42H44N6O3SSi requires 740.30); νmax (KBr)/cm-1: 2958, 2930, 2856, 1516 and 1463; δH (400 
MHz, DMSO-d6) 0.97 (9H, s, tBu), 1.90 (1H, m, H3y), 2.00 
(3H, s, O=C-CH3), 2.10 (1H, m, H3x), 2.97 (2H, m, H4y + 
H4x), 3.84 (3H, s, OCH3), 3.93 (2H, m, H1y + H1x), 4.20 (1H, 
m, H2), 6.34 (1H, d, J = 6.8 Hz, H9’’), 6.86-6.87 (2H, m, H7’’ 
+ H8’’), 7.01 (1H, d, J = 8.1 Hz, H4’’), 7.06 (1H, dd, J = 6.8, 
2.0 Hz, H6’’), 7.13 (1H, dd, J = 8.1, 2.0 Hz, H3’’), 7.16 (2H, 
m, H3’ + H5’), 7.31 (4H, m, H3’’’ + H5’’’ + H3’’’’ + H5’’’’), 
7.37 (1H, s, H1’’), 7.40 (2H, m, H4’’’ + H4’’’’), 7.60 (4H, m, 
H2’’’ + H6’’’ + H2’’’’ + H6’’’’), 7.81 (2H, m, H2’ + H6’), 
9.90 (1H, s, NH); δC (100 MHz, DMSO-d6) 18.8 (C-tBu), 19.8 
(C4), 23.9 (O=C-CH3), 26.8 (tBu, 3C), 32.1 (C3), 51.4 (C1), 
55.6 (OCH3), 68.3 (C2), 106.8 (C1’’), 113.3 (C3’’), 114.9 (C3’ 
+ C5’), 115.7 (C9’’), 117.8 (C2’’), 121.2 (C2’ + C6’), 122.7 
(C7’’), 124.9 (C5a’’), 127.2 (C4’’ + C6’’ + C8’’), 127.6 (C3’’’ 
+ C5’’’), 127.7 (C3’’’’ + C5’’’’), 129.6 (C1’), 129.7 (C4’’’), 
129.8 (C4’’’’), 132.8 (C1’’’ + C1’’’’), 135.4 (C2’’’ + C6’’’ + 
C2’’’’ + C6’’’’), 139.2 (C4a’’), 143.9 (C9a’’), 145.8 (C10a’’), 
160.0 (C4’), 165.9 (Ctetrazole), 168.2 (O=C-CH3). 
 
1-(2-Chloro-5-oxido-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (10) 
This compound was prepared as described in the literature.12 
 
 4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(5-oxido-
10H-phenothiazin-10-yl)butan-2-ol (11) 
This compound was obtained from reaction of 1-(2-chloro-
5-oxido-10H-phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butan-2-ol (10, 0.30 g, 0.61 mmol) and 
diethylamine (0.12 mL, 1.21 mmol) by using the reaction 
conditions with preparation of derivatives 4h,i (see above). 
The reaction time was 7 h. After column chromatography the 
crude product was recrystallized from ethyl acetate and white 
crystals were collected by filtration, 0.11 g (39%); mp 167-169 
°C; (Found: C, 62.25; H, 4.70; N, 14.89; C24H23N5O3S requires 
C, 62.46; H, 5.02; N, 15.17%); m/z (EI) [M+H]+: 462.20 
(C24H23N5O3S requires 461.15); νmax (KBr)/cm-1: 3374, 2926, 
1585, 1515 and 1462; δH (400 MHz, DMSO-d6) 1.84 (1H, m, 
H3y), 2.06 (1H, m, H3x), 2.96 (1H, m, H4y), 3.07 (1H, m, 
H4x), 3.86 (3H, s, OCH3), 4.06 (1H, m, H2), 4.42 (1H, m, 
H1y), 4.51 (1H, m, H1x), 5.16 (1H, br. s, OH), 7.18 (2H, m, 
H3’ + H5’), 7.28 [7.29] (2H, m, H3’’ + H7’’), 7.67 [7.65] (2H, 
m, H2’’ + H8’’), 7.92 (2H, m, H2’ + H6’), 7.93 [7.76] (4H, m, 
H1’’ + H4’’ + H6’’ + H9’’); δC (100 MHz, DMSO-d6) 21.0 
(C4), 32.1 (C3), 53.3 (C1), 55.6 (OCH3), 67.2 (C2), 115.0 (C3’ 
+ C5’), 118.3 [117.7] (C1’’ + C9’’), 121.3 (C2’ + C6’), 122.0 
[121.8] (C3’’ + C7’’), 125.3 [125.9] (C4a’’ + C5a’’), 129.6 
(C1’), 130.1 [130.0] (C4’’ + C6’’), 132.5 [132.7] (C2’’+ C8’’), 
139.2 [138.5] (C9a’’ + C10a’’), 160.1 (C4’), 166.4 (Ctetrazole). 
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-[5-oxido-2-
(4-oxidomorpholin-4-yl)-10H-phenothiazin-10-yl]butan-2-
ol (12) 
To a solution of 4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]-
1-(2-morpholin-4-yl-5-oxido-10H-phenothiazin-10-yl)butan-2-
ol (4h, 0.04 g, 0.07 mmol) in abs. dichloromethane (1 mL) m-
CPBA (0.02 g, 0.11 mmol)/abs. dichloromethane (0.5 mL) was 
added dropwise at 0 °C. The clear purple reaction mixture 
became a white suspension. After completion of the reaction 
(23 h), the mixture was cooled to 0 °C, water was added and 
stirred for 45 min. It was made alkaline with 10% aqueous 
Na2CO3 and extracted with dichloromethane (3 x 0.5 mL). The 
organic phase was dried over Na2SO4, filtered and 
concentrated. The crude product was purified by column 
chromatography on silica gel using the eluent 
chloroform:methanol = 15:1, then 10:1 to give white-grey 
crystals, 34 mg (83%); mp 152-154 °C; (Found: C, 59.80; H, 
5.30; N, 14.84; C28H30N6O5S requires C, 59.77; H, 5.37; N, 
14.94%); m/z (EI) [M+H]+: 563.50 (C28H30N6O5S requires 
562.20); νmax (KBr)/cm-1: 2963, 2927, 1588, 1515 and 1260; δH 
(400 MHz, DMSO-d6) 1.86 (1H, m, H3y), 2.08 (1H, m, H3x), 
2.87 (2H, m, H3y’’’ + H5y’’’), 2.96 (1H, m, H4y), 3.07 (1H, 
m, H4x), 3.79 (2H, m, H2y’’’ + H6y’’’), 3.85 (3H, s, OCH3), 
4.08 (1H, m, H2), 4.14 (2H, m, H3x’’’ + H5x’’’), 4.44 (2H, m, 
H2x’’’ + H6x’’’), 4.47 (1H, m, H1y), 4.55 (1H, m, H1x), 5.17 
(1H, d, J = 6.2 Hz, OH), 7.16 (2H, m, H3’ + H5’), 7.32 [7.31] 
(1H, m, H7’’), 7.68 [7.71] (1H, m, H8’’), 7.91 (2H, m, H2’ + 
H6’), 7.95 [7.78] (1H, m, H9’’), 7.97 [8.06] (1H, m, H6’’), 
8.02 [8.07] (1H, m, H3’’), 8.07 [7.96] (1H, m, H4’’), 8.72 
[8.77] (1H, m, H1’’); δC (100 MHz, DMSO-d6) 21.0 (C4), 32.2 
(C3), 53.3 (C1), 55.6 (OCH3), 61.7 (C2’’’ + C6’’’), 66.7 (C3’’’ 
+ C5’’’), 66.8 (C2), 110.9 [111.2] (C1’’), 114.7 [114.3] (C3’’), 
115.0 (C3’ + C5’), 118.3 [117.7] (C9’’), 121.3 (C2’ + C6’), 
122.3 [122.4] (C7’’), 125.9 [125.3] (C2’’), 129.6 (C1’), 129.6 
[130.2] (C6’’), 130.7 [129.6] (C4’’), 130.8 [130.3] (C5a’’), 
132.7 [132.9] (C8’’), 138.8 [138.4] (C9a’’), 139.4 [138.9] 
(C10a’’), 159.2 [159.1] (C4a’’), 160.1 (C4’), 166.3 (Ctetrazole). 
 
General procedure for the preparation of O-tert-
butyldiphenylsilyl protected sulfoxide and sulfone 
derivatives (13, 14) 
To the solution of the appropriate protected hydroxy 
compound (8 or 13, 0.56 mmol) in abs. dichloromethane, m-
CPBA (0.12 g, 0.72 mmol)/abs. dichloromethane (6 mL) was 
added dropwise at 0 °C. The clear purple reaction mixture 
became a white suspension. After completion of the reaction 
(2-6 h), the mixture was cooled to 0 °C, water was added and 
stirred for 45 min. It was made alkaline with 10% aqueous 
Na2CO3 and extracted with dichloromethane (three times). The 
organic phase was dried over Na2SO4, filtered and 
concentrated. The crude product was purified by column 
chromatography on silica gel using the eluent n-hexane:ethyl 
acetate = 2:1 ill. 1:1 to give white crystals. 
 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine 5-oxide (13) 
This compound was obtained from 10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine (8, 0.40 g) to 
give the product as white crystals, 0.36 g (88%); mp 64-68 °C; 
(Found: C, 65.28; H, 5.60; N, 9.17; C40H40ClN5O3SSi requires 
C, 65.42; H, 5.49; N, 9.54%); m/z (EI) [M+H]+: 734.30 
(C40H40ClN5O3SSi requires 733.23); νmax (KBr)/cm-1: 2931, 
1581, 1516, 1456 and 1256; δH (300 MHz, CDCl3) 0.93 (9H, 
s), 2.04 (1H, m), 2.17 (1H, m), 2.99 (2H, m), 3.88 (3H, s), 
4.10-4.52 (3H, m), 6.62 (1H, m), 7.00 (2H, m), 7.07-7.45 
(10H, m), 7.54-7.80 (6H, m), 7.89 (2H, m); δC (75 MHz, 
CDCl3) 19.4, 20.8, 27.0 (3C), 32.5, 51.6, 55.9, 69.2, 114.7 
(2C), 116.3, 116.5, 117.5, 121.5 (2C), 122.6, 122.7, 123.0, 
124.5, 126.2, 128.0 (2C), 128.1 (2C), 129.5, 130.3, 130.6, 
131.4, 131.9, 132.7, 133.2, 136.0 (4C), 138.8, 141.0, 160.5, 
166.2. 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine 5,5-dioxide (14) 
This compound was obtained from 10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine 5-oxide (13, 
0.42 g, 0.35 mmol) to give the product as white crystals, 0.43 g 
(quant.); mp 62-67 °C; (Found: C, 64.40; H, 5.47; N, 9.27; 
C40H40ClN5O4SSi requires C, 64.02; H, 5.37; N, 9.33%); m/z 
(EI) [M+H]+: 750.30 (C40H40ClN5O4SSi requires 749.23); νmax 
(KBr)/cm-1: 2930, 1585, 1516, 1461 and 1256; δH (300 MHz, 
CDCl3) 1.00 (9H, s), 1.96 (1H, m), 2.14 (1H, m), 2.98 (2H, t, J 
= 7.5 Hz), 3.88 (3H, s), 4.10-4.43 (3H, m), 6.66 (1H, d, J = 8.1 
Hz), 7.00 (2H, m), 7.13-7.28 (4H, m), 7.37-7.45 (6H, m), 7.68-
7.71 (4H, m), 7.85-7.97 (4H, m); δC (75 MHz, CDCl3) 19.5, 
20.7, 27.1 (3C), 32.0, 51.7, 55.9, 69.1, 114.7 (2C), 117.1, 
117.2, 121.5 (2C), 122.8 (2C), 123.6, 124.1, 125.2, 125.9, 
128.1 (2C), 128.2 (2C), 130.3, 130.4, 130.7, 133.0, 133.2, 
133.5, 136.1 (4C), 139.4, 141.0, 143.1, 160.5, 166.2. 
 
General procedure for preparation of 10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-amino-10H-phenothiazine 5,5-dioxide 
derivatives (15) 
 A round-bottomed flask was charged with Pd-catalyst: 
Pd2(dba)3 (10 mol%), ligand: XPhos (20 mol%), 10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine 5,5-dioxide 
(14), secondary amine, base: NaOtBu, and dry toluene (5 mL). 
The flask was flushed with argon for 5 min. The resulting 
mixture was heated under reflux with magnetic stirring for 70-
90 min. After cooling down to rt the reaction mixture was 
concentrated and the residue was purified by flash 
chromatography on silica gel using the eluent 
dichloromethane, then n-hexane:ethyl acetate = 2:1 and 1:1 to 
give the final product as beige amorphous solid. 
 
10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-N,N-diethyl-10H-
phenothiazin-2-amine 5,5-dioxide (15f) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine 5,5-dioxide 
(14, 0.35 g, 0.47 mmol) and diethylamine (0.10 mL, 0.93 
mmol). The reaction time was 70 min. After flash 
chromatography the product was isolated as beige amorphous 
solid, 0.11 g (58%); mp 71-75 °C; (Found: C, 66.87; H, 6.42; 
N, 9.89; C44H50N6O4SSi requires C, 67.15; H, 6.40; N, 
10.68%); m/z (EI) [M+H]+: 787.70 (C44H50N6O4SSi requires 
786.34); νmax (KBr)/cm-1: 3430, 2931, 1594, 1516 and 1471; δH 
(300 MHz, CDCl3) 1.00 (9H, s), 1.18 (6H, t, J = 6.9 Hz), 2.04 
(1H, m), 2.16 (1H, m), 3.02 (2H, t, J = 7.5 Hz), 3.38 (4H, q, J 
= 6.9 Hz), 3.88 (3H, s), 4.06-4.41 (3H, m), 6.21-6.25 (2H, m), 
6.45 (1H, d, J = 9.0 Hz), 6.97-7.04 (4H, m), 7.36-7.50 (6H, m), 
7.72-7.74 (5H, m), 7.86-7.89 (3H, m); δC (75 MHz, CDCl3) 
12.5 (2C), 19.3, 20.6, 26.8 (3C), 31.6, 44.6 (2C), 51.2, 55.6, 
69.2, 97.0, 106.4, 113.1, 114.4 (2C), 116.5, 121.4 (2C), 122.6, 
123.9, 125.0, 127.0, 127.8 (2C), 128.0 (2C), 130.0, 130.1, 
130.5, 131.8, 132.8, 133.9, 135.8 (2C), 136.0 (2C), 141.0, 
144.5, 151.1, 160.1, 166.3. 
 
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-morpholin-4-yl-
10H-phenothiazine 5,5-dioxide (15h) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine 5,5-dioxide 
(14, 0.20 g, 0.27 mmol) and morpholine (0.05 mL, 0.53 
mmol). The reaction time was 90 min. After flash 
chromatography the product was isolated as beige amorphous 
solid, 0.20 g (92%); mp 56-60 °C; (Found: C, 65.85; H, 6.09; 
N, 10.30; C44H48N6O5SSi requires C, 65.97; H, 6.04; N, 
10.49%); m/z (EI) [M+H]+: 801.50 (C44H48N6O5SSi requires 
800.32); νmax (KBr)/cm-1: 2930, 1694, 1516, 1464 and 1256; δH 
(300 MHz, CDCl3) 0.98 (9H, s), 2.04 (1H, m), 2.13 (1H, m), 
2.97 (2H, t, J = 7.5 Hz), 3.10-3.18 (4H, m), 3.83 (4H, m), 3.87 
(3H, s), 4.09-4.43 (3H, m), 6.47-6.67 (3H, m), 6.98-7.45 (11H, 
m), 7.70-7.93 (7H, m); δC (75 MHz, CDCl3) 19.5, 20.6, 27.0 
(3C), 32.0, 48.2 (2C), 51.5, 55.9, 66.8 (2C), 69.2, 101.3, 109.5, 
114.7 (2C), 116.8, 116.9, 121.5 (2C), 122.0, 123.1, 125.1, 
126.7, 128.0 (2C), 128.2 (2C), 130.2, 130.4, 130.5, 132.4, 
133.0, 134.0, 136.0 (2C), 136.2 (2C), 141.4, 144.0, 154.7, 
160.5, 166.4. 
 
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-(4-
methylpiperazin-1-yl)-10H-phenothiazine 5,5-dioxide (15i) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine 5,5-dioxide 
(14, 0.20 g, 0.27 mmol) and N-methylpiperazine (0.06 mL, 
0.53 mmol). The reaction time was 70 min. After flash 
chromatography the product was isolated as beige amorphous 
solid, 0.20 g (92%); mp 81-86 °C; (Found: C, 66.31; H, 6.29; 
N, 11.94; C45H51N7O4SSi requires C, 66.39; H, 6.31; N, 
12.04%); m/z (EI) [M+H]+: 814.30 (C45H51N7O4SSi requires 
813.35); νmax (KBr)/cm-1: 3418, 2932, 1593, 1516 and 1456; δH 
(300 MHz, CDCl3) 1.00 (9H, s), 1.98 (1H, m), 2.14 (1H, m), 
2.38 (3H, s), 2.56 (4H, t, J = 4.8 Hz), 2.98 (2H, t, J = 7.2 Hz), 
3.28 (4H, t, J = 4.8 Hz), 3.88 (3H, s), 4.10 (1H, m), 4.21 (1H, 
m), 4.41 (1H, m), 6.39 (1H, d, J = 6.9 Hz), 6.52 (1H, s), 6.66 
(1H, d, J = 9.0 Hz), 6.97-7.13 (4H, m), 7.36-7.47 (6H, m), 
7.71-7.79 (5H, m), 7.85-7.92 (3H, m); δC (75 MHz, CDCl3) 
19.5, 20.7, 27.1 (3C), 31.9, 46.2, 47.9 (2C), 51.4, 54.9 (2C), 
55.9, 69.2, 101.4, 109.8, 114.7 (2C), 116.3, 116.9, 121.5 (2C), 
122.0, 123.1, 125.0, 126.9, 128.0 (2C), 128.2 (2C), 130.2, 
130.4, 130.7, 132.4, 133.0, 134.1, 136.1 (2C), 136.2 (2C), 
141.3, 144.2, 154.5, 160.4, 166.4. 
 
General procedure for the preparation of 1-(2-amino-
5,5-dioxido-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol derivatives 
(16)  
To the solution of 10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-
[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-amino-10H-
phenothiazine 5,5-dioxide derivative (15, 0.22 mmol) in 
anhydrous THF (15 mL) in a dried, round-bottomed flask 
equipped with a side arm and cooled to 0 °C in an argon 
atmosphere was added the solution of TBAF (0.33 mmol)/abs. 
THF (1 mL). The reaction mixture was allowed to warm up to 
rt. After the completion of the reaction as specified (2.5-4.5 h) 
the reaction mixture was evaporated. The residue was purified 
by column chromatography on silica gel using the eluent n-
hexane:ethyl acetate = 2:1 then 1:1 to give the product. 
 
1-[2-(Diethylamino)-5,5-dioxido-10H-phenothiazin-10-
yl]-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol 
(16f) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-N,N-diethyl-10H-phenothiazin-2-amine 
5,5-dioxide (15f, 0.25 g, 0.32 mmol) and TBAF (0.12 g, 0.48 
mmol)/abs. THF (1 mL). The reaction time was 2.5 h. After 
column chromatography yellow amorphous solid were 
isolated, 0.14 g (78%); mp 49-52 °C; (Found: C, 61.13; H, 
5.48; N, 14.98; C28H32N6O4S requires C, 61.30; H, 5.88; N, 
15.32%); m/z (EI) [M+H]+: 549.30 (C28H32N6O4S requires 
548.22); νmax (KBr)/cm-1: 2968, 2928, 1593, 1516 and 1470; δH 
(400 MHz, DMSO-d6) 1.12 (6H, t, J = 6.9 Hz, 
N(CH2)2(CH3)2), 1.84 (1H, dddd, J = 14.2, 9.4, 9.0, 5.0 Hz, 
H3y), 2.07 (1H, m, H3x), 2.99 (1H, ddd, J = 15.2, 9.0, 7.1 Hz, 
H4y), 3.08 (1H, ddd, J = 15.2, 9.4, 5.2 Hz, H4x), 3.42 (4H, m, 
N(CH2)2(CH3)2), 3.85 (3H, s, OCH3), 4.15 (1H, m, H2), 4.24 
(1H, dd, J = 15.0, 4.8 Hz, H1y), 4.32 (1H, dd, J = 15.0, 7.3 Hz, 
H1x), 5.22 (1H, d, J = 5.3 Hz, OH), 6.63 (1H, m, H3’’), 6.64 
(1H, s, H1’’), 7.16 (2H, m, H3’ + H5’), 7.25 (1H, dd, J = 7.9, 
 7.3 Hz, H7’’), 7.62 (1H, m, H8’’), 7.65 (1H, m, H4’’), 7.69 
(1H, d, J = 8.6 Hz, H9’’), 7.87 (1H, dd, J = 7.9, 1.4 Hz, H6’’), 
7.90 (2H, m, H2’ + H6’); δC (100 MHz, DMSO-d6) 12.2 
(N(CH2)2(CH3)2, 2C), 21.0 (C4), 32.6 (C3), 44.0 
(N(CH2)2(CH3)2, 2C), 53.5 (C1), 55.7 (OCH3), 66.8 (C2), 97.5 
(C1’’), 106.3 (C3’’), 111.2 (C4a’’), 115.0 (C2’ + C6’), 117.8 
(C9’’), 121.3 (C2’ + C6’ + C7’’), 121.8 (C6’’), 124.0 (C4’’), 
125.3 (C5a’’), 129.6 (C1’), 132.5 (C8’’), 141.4 (C9a’’), 143.0 
(C10a’’), 150.8 (C2’’), 160.1 (C4’), 166.4 (Ctetrazole). 
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-
morpholin-4-yl-5,5-dioxido-10H-phenothiazin-10-yl)butan-
2-ol (16h) 
This compound was obtained from the reaction of 10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-morpholin-4-yl-10H-phenothiazine 5,5-
dioxide (15h, 0.18 g, 0.22 mmol) and TBAF (0.09 g, 0.33 
mmol)/abs. THF (1 mL). The reaction time was 4.5 h. After 
column chromatography yellow amorphous solid were 
isolated, 0.10 g (82%); mp 71-76 °C. The air sensitive product 
was stored in an argon atmosphere; (Found: C, 59.41; H, 5.34; 
N, 14.93; C28H30N6O5S requires C, 59.77; H, 5.37; N, 14.94%); 
m/z (EI) [M+H]+: 563.30 (C28H30N6O5S requires 562.20); νmax 
(KBr)/cm-1: 2924, 2853, 1593, 1516 and 1468; δH (400 MHz, 
DMSO-d6) 1.81 (1H, m, H3y), 2.04 (1H, m, H3x), 2.97 (1H, 
m, H4y), 3.06 (1H, m, H4x), 3.30 (4H, m, N-(CH2)2), 3.74 
(4H, m, O-(CH2)2), 3.84 (3H, s, OCH3), 4.10 (1H, m, H2), 4.31 
(1H, m, H1y), 4.36 (1H, m, H1x), 5.18 (1H, d, J = 5.3 Hz, 
OH), 6.92 (1H, m, H3’’), 7.01 (1H, s, H1’’), 7.16 (2H, m, H3’ 
+ H5’), 7.28 (1H, m, H7’’), 7.65 (1H, m, H8’’), 7.71 (1H, m, 
H9’’), 7.72 (1H, m, H4’’), 7.89 (1H, m, H6’’), 7.90 (2H, m, 
H2’ + H6’); δC (100 MHz, DMSO-d6) 20.9 (C4), 32.4 (C3), 
47.3 (N-(CH2)2, 2C), 53.1 (C1), 55.6 (OCH3), 65.8 (O-(CH2)2, 
2C), 66.6 (C2), 101.4 (C1’’), 109.1 (C3’’), 114.5 (C4a’’), 
115.0 (C2’ + C6’), 117.9 (C9’’), 121.3 (C2’ + C6’ + C6’’), 
121.6 (C7’’), 123.6 (C5a’’), 125.0 (C4’’), 129.6 (C1’), 132.7 
(C8’’), 141.4 (C9a’’), 142.8 (C10a’’), 154.2 (C2’’), 160.1 
(C4’), 166.3 (Ctetrazole). 
 
4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-[2-(4-
methylpiperazin-1-yl)-5,5-dioxido-10H-phenothiazin-10-
yl]butan-2-ol (16i) 
This compound was obtained from the reaction of 10-(2-
((tert-butyldiphenylsilyl)oxy)-4-(2-(4-methoxyphenyl)-2H-
tetrazol-5-yl)butyl)-2-(4-methylpiperazin-1-yl)-10H-
phenothiazine-5,5-dioxide (15i, 0.20 g, 0.25 mmol) and 
tetrabutylammonium fluoride (0.10 g, 0.37 mmol)/abs. THF (1 
mL). The reaction time was 4.5 h. The crude product was 
purified by column chromatography on silica gel using the 
eluent chloroform:methanol = 15:1 then 10:1. Yellow 
amorphous solid were isolated, 0.13 g (88%); mp 74-80 °C. 
The air sensitive product was stored in an argon atmosphere; 
(Found: C, 60.41; H, 5.70; N, 16.75; C29H33N7O4S requires C, 
60.50; H, 5.78; N, 17.03%); m/z (EI) [M+H]+: 576.20 
(C29H33N7O4S requires 575.23); νmax (KBr)/cm-1: 2937, 2842, 
1593, 1516 and 1455; δH (400 MHz, DMSO-d6) 1.83 (1H, m, 
H3y), 2.05 (1H, m, H3x), 2.21 (3H, s, H3C-N-(CH2)2), 2.42 
(4H, m, H3C-N-(CH2)2), 2.97 (1H, m, H4y), 3.07 (1H, m, 
H4x), 3.33 (4H, m, H3C-N-(CH2)2), 3.84 (3H, s, OCH3), 4.10 
(1H, m, H2), 4.30 (2H, m, H1y + H1x), 5.18 (1H, d, J = 5.3 
Hz, OH), 6.92 (1H, m, H3’’), 6.98 (1H, s, H1’’), 7.16 (2H, m, 
H3’ + H5’), 7.28 (1H, m, H7’’), 7.64 (1H, m, H8’’), 7.69 (1H, 
m, H4’’), 7.71 (1H, m, H9’’), 7.88 (1H, m, H6’’), 7.90 (2H, m, 
H2’ + H6’); δC (100 MHz, DMSO-d6) 20.9 (C4), 32.4 (C3), 
45.6 (N-CH3), 47.0 (N-(CH2)2, 2C), 53.1 (C1), 54.3 (H3C-N-
(CH2)2, 2C), 55.7 (OCH3), 66.6 (C2), 101,4 (C1’’), 109.3 
(C3’’), 114.0 (C4a’’), 115.0 (C2’ + C6’), 117.9 (C9’’), 121.3 
(C2’ + C6’), 121.5 (C7’’), 121.9 (C6’’), 123.6 (C4’’), 125.1 
(C5a’’), 129.6 (C1’), 132.7 (C8’’), 141.4 (C9a’’), 142.8 
(C10a’’), 154.1 (C2’’), 160.1 (C4’), 166.3 (Ctetrazole). 
(2Z)-4-{1-[(2-chloro-10H-phenothiazin-10-yl)methyl]-3-
[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]propoxy}-4-oxobut-
2-enoic acid (17) 
To a solution of racemic 1-(2-chloro-10H-phenothiazin-10-
yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol (5, 
4.15 g, 8.64 mmol) in abs. dichloromethane (30 mL), abs. 
triethylamine (2.59 mL, 18.70 mmol) was added and the 
mixture was stirred at rt. After 30 min, maleic anhydride (1.59 
g, 16.17 mmol) was added to the mixture and it was heated up 
and refluxed for 9.5 h. The mixture was then cooled to rt, the 
pH was adjusted to acidic with 10% aqueous HCl solution. 
After separation, the organic phase was washed with water, 
dried over Na2SO4, filtered and concentrated. The crude 
product (foam) was triturated with n-hexane, the mixture was 
cooled whereupon crystals deposited. The product was filtered 
off to yield yellow crystals, 4.98 g (quant.); mp 56-60 °C; 
(Found: C, 57.81; H, 3.96; N, 11.99; C28H24ClN5O5S requires 
C, 58.18; H, 4.18; N, 12.12%); m/z (EI) [M+H]+: 578.30 
(C28H24ClN5O5S requires 577.12); νmax (KBr)/cm-1: 2925, 2361, 
1516, 1458 and 1256; δH (300 MHz, CDCl3) 2.29 (1H, m, 
H3y), 2.39 (1H, m, H3x), 3.07 (2H, t, J = 7.8 Hz, H4y + H4x), 
3.88 (3H, s, OCH3), 4.08 (1H, dd, J = 13.8, 6.6 Hz, H1y), 4.17 
(1H, dd, J = 13.8, 6.3 Hz, H1x), 5.56 (1H, m, H2), 6.21 (1H, d, 
J = 12.9 Hz, CH=CH-COOH), 6.40 (1H, d, J = 12.9 Hz, 
CH=CH-COOH), 6.90-7.20 (10H, m, H3’ + H5’ + H1’’ + H3’’ 
+ H4’’ + H6’’ + H7’’ + H8’’ + H9’’ + COOH), 7.93 (2H, m, 
H2’ + H6’); δC (75 MHz, CDCl3) 21.4 (C4), 29.9 (C3), 49.8 
(C1), 55.9 (OCH3), 72.6 (C2), 114.9 (C3’ + C5’), 116.4 (CH), 
116.6 (CH), 121.5 (C2’ + C6’), 123.4 (CH), 124.0 (CH), 125.3 
(C), 126.5 (C), 127.9 (CH), 128.2 (CH), 128.6 (CH), 128.7 
(CH), 130.4 (C), 133.7 (C), 136.1 (CH), 144.3 (C), 146.5 (C), 
160.8 (C4’), 164.7 (COO), 165.6 (Ctetrazole), 167.0 (COOH). 
 
Resolution of racemic (2Z)-4-{1-[(2-chloro-10H-
phenothiazin-10-yl)methyl]-3-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]propoxy}-4-oxobut-2-enoic acid (17) with S-(-
)-phenylethylamine23d 
 
Diastereomeric saltcrystal (18)  
Racemic 4-((1-(2-chloro-10H-phenothiazin-10-yl)-4-(2-(4-
methoxyphenyl)-2H-tetrazol-5-yl)butan-2-yl)oxy)-4-oxobut-2-
enoic acid (17, 5.72 g, 9.90 mmol) was dissolved in ethyl 
acetate (60 mL), and S-(-)-phenylethylamine (0.64 mL, 4.95 
mmol) was added to the solution. The reaction mixture was 
stirred at rt for 2 h. Precipitation of the diastereomeric saltcrystal 
(18) commenced in a few minutes. The precipitated 
diastereomer salt was collected by filtration and washed with 
ethyl acetate (3 x 10 mL). The white crystals were 
recrystallized from hot ethyl acetate and cooled slowly 
(recrystallization from ethyl acetate was repeated once again) 
to give 4-((1-(2-chloro-10H-phenothiazin-10-yl)-4-(2-(4-
methoxyphenyl)-2H-tetrazol-5-yl)butan-2-yl)oxy)-4-oxobut-2-
enoic acid (S)-phenylethylamine salt 18 as white crystals, 2.49 
g (75%); mp 147-150 °C; [α] 25D  = - 4.90 (c 0.368, methanol); 
(Found: C, 61.51; H, 5.03; N, 11.67; C36H35ClN6O5S requires 
 C, 61.84; H, 5.05; N, 12.02%); νmax (KBr)/cm-1: 3421, 2934, 
2540, 1515 and 1460. 
 
(-)-4-{1-[(2-Chloro-10H-phenothiazin-10-yl)methyl]-3-
[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]propoxy}-4-oxobut-
2-enoic acid ((-)-17) 
 
The recrystallized diastereomeric salt (18, 2.36 g, 3.37 
mmol) was dissolved in a mixture of methanol (52 mL) and 
dichloromethane (15 mL) and stirred at rt. To the reaction 
mixture 10% aqueous HCl solution (14.13 mL) was added. 
After 4 h, the phases were separated and the organic phase was 
extracted with 10% aqueous HCl solution (2 x 5 mL), dried 
over Na2SO4, filtered and concentrated. The crude product was 
triturated with n-hexane and yellow crystals were collected by 
filtration, 1.94 g (99.8%); [α] 25D  = - 11.00 (c 0.310, 
chloroform); (Found: C, 57.81; H, 3.96; N, 11.99; 
C28H24ClN5O5S requires C, 58.18; H, 4.18; N, 12.12%); νmax 
(KBr)/cm-1: 2929, 1516, 1458, 1256 and 1170. 
 
(-)-1-(2-Chloro-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol ((-)-5) 
(-)-4-{1-[(2-Chloro-10H-phenothiazin-10-yl)methyl]-3-[2-
(4-methoxyphenyl)-2H-tetrazol-5-yl]propoxy}-4-oxobut-2-
enoic acid ((-)-17, 1.75 g, 3.02 mmol) was dissolved in 
dichloromethane (37 mL) at rt and the solution of NaOH (0.54 
g, 13.6 mmol)/H2O (2 mL) was added to the mixture then 
refluxed for 7.5 h. After cooling, water (30 mL) was added to 
the mixture, it was acidified with 10% aqueous HCl solution 
and extracted with dichloromethane (3 x 20 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated. The 
crude product was purified by flash chromatography on silica 
gel using the eluent n-hexane:ethyl acetate = 2:1 then 1:1. The 
product (foam) was triturated with diethyl ether and the 
mixture was cooled whereupon crystals deposited. The 
product, white crystals were collected by filtration, 1.25 g 
(86%); mp 90-92 °C; [α] 25D  = - 21.30 (c 0.282, chloroform); 
ee: 99.9+%; HPLC: using the eluent n-hexane:2-propanol + 
0.1% diethylamine = 70:30, retention time: 15.2 min; (Found: 
C, 59.72; H, 4.70; N, 14.30; C24H22ClN5O2S requires C, 60.06; 
H, 4.62; N, 14.59%); m/z (EI) [M+H]+: 480.20 
(C24H22ClN5O2S requires 479.12); νmax (KBr)/cm-1: 3422, 2929, 
1515, 1461 and 1259. 
 
(+)-4-{1-[(2-chloro-10H-phenothiazin-10-yl)methyl]-3-
[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]propoxy}-4-oxobut-
2-enoic acid ((+)-17) 
The mother liquor obtained after separation of crystalline  
18 was evaporated to give a solid (19, 3.44g) containing a 
mixture of the non-reacted part of 17, i.e. (+)-17 and, 
additionally, traces of 18. This mixture  was dissolved in ethyl 
acetate (20 mL), stirred at rt and, then, 10% aqueous HCl 
solution (1.35 mL) was added (this amount of HCl was 
calculated as an excess for the assumed amount of 18 being 
present in the mixture 19). After 50 min, the phases were 
separated and the organic phase was washed with 10% aqueous 
HCl solution (2 x 0.5 mL), dried over Na2SO4, filtered and 
concentrated. The crude product (foam) was triturated with n-
hexane, yellow crystals deposited and were collected by 
filtration. As the mass spectrum still indicated the presence of 
the reagent S-(-)-phenylethylamine, the hydrolysis was 
repeated again. Yield: 3.07 g (107%, calculated for the 
expected amount of (+)-monoester: (+)-17); for the crude 
product: [α] 25D = + 14.00 (c 0.470, methanol); νmax (KBr)/cm-1: 
2931, 1516, 1458, 1256 and 1170. 
 
(+)-1-(2-chloro-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol ((+)-5) 
The (+)-monoester ((+)-17, 2.84 g, 4.90 mmol) was 
dissolved in abs. dichloromethane (59 mL) at rt and the 
solution of NaOH (0.88 g, 22.09 mmol) in water (2.6 mL) was 
added to the reaction mixture. The mixture was stirred and 
heated up to reflux. After completion (4 h), the mixture was 
allowed to cool down to rt, water (40 mL) was added to the 
solution, acidified with 10% aqueous HCl solution and 
extracted with dichloromethane (3 x 15 mL). The combined 
organic phase was dried over Na2SO4, filtered and 
concentrated. The residue was purified by flash 
chromatography on silica gel using the eluent n-hexane:ethyl 
acetate = 2:1 then 1:1. The crude product (foam) was triturated 
with diethyl ether, the mixture was cooled, and the white 
crystals were collected by filtration (twice), total yield: 1.85 g 
(74%) (m1= 1.57 g, ee: 89% + m2= 0.28 g, ee: 94%); mp 90-92 
°C; [α] 25D = + 21.20 (c 0.358, chloroform (m2)). HPLC: using 
the eluent n-hexane:2-propanol + 0.1% diethylamine = 70:30, 
retention time: 10.1 min; (Found: C, 59.97; H, 4.68; N, 14.45; 
C24H22ClN5O2S requires C, 60.06; H, 4.62; N, 14.59%); m/z 
(EI) [M+H]+: 480.20 (C24H22ClN5O2S requires 479.12); νmax 
(KBr)/cm-1: 3422, 2929, 1515, 1461 and 1259. 
 
General procedure for the preparation of (-)- and (+) 1-
(2-amino-10H-phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-
2H-tetrazol-5-yl]butan-2-ol derivatives ((-)-3 and (+)-3) by 
desilylation of 10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-
2-amine derivatives ((-)-9 and (+)-9) 
The procedure followed the aforementioned preparation of 
racemic 1-(2-amino-10H-phenothiazin-10-yl)-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol derivatives (3) by 
desilylation of 10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-2-
amine derivatives (9). 
 
(-)-1-[2-(Diethylamino)-10H-phenothiazin-10-yl]-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol ((-)-3f) 
This compound was obtained from (-)-10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-N,N-diethyl-10H-phenothiazin-2-amine ((-
)-9f, 0.20 g, 0.26 mmol). The crude product was purified by 
flash chromatography on silica gel using the eluent 
dichloromethane, then n-hexane:ethyl acetate = 2:1 to give 
white amorphous solid, 0.09 g (66%); ee: 99.6%; [α] 25D = - 
9.98 (c 0.259, chloroform); HPLC: using the eluent n-
hexane:2-propanol + 0.1% diethylamine = 70:30, retention 
time: 22.1 min. 
 
(-)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-
morpholin-4-yl-10H-phenothiazin-10-yl)butan-2-ol ((-)-3h) 
 This compound was obtained from (S)-(-)-10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-morpholin-4-yl-10H-phenothiazine ((-)-
9h, 0.31 g, 0.40 mmol). The crude product was purified by 
flash chromatography on silica gel using the eluent n-
hexane:ethyl acetate = 4:1 to give beige amorphous solid, 0.21 
g (98%); ee: 99.9+%; [α] 25D = - 15.24 (c 0.289, chloroform). 
HPLC: using the eluent n-hexane:2-propanol +  0.1% 
diethylamine = 70:30, retention time: 17.4 min. 
 
(-)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]-1-[2-(4-
methylpiperazin-1-yl)-10H-phenothiazin-10-yl]butan-2-ol 
((-)-3i) 
This compound was obtained from (-)-10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-(4-methylpiperazin-1-yl)-10H-
phenothiazine ((-)-9i, 0.39 g, 0.49 mmol). The crude product 
was purified by flash chromatography on silica gel using the 
eluent chloroform:methanol = 30:1, 15:1 then 10:1 to give a 
brown oil, 0.25 g (95%); ee: 99.8%; [α] 25D = - 4.42 (c 0.328, 
chloroform); HPLC: using the eluent n-hexane:2-propanol +  
0.1% diethylamine = 70:30, retention time: 23.8 min. 
 
(+)-1-[2-(Diethylamino)-10H-phenothiazin-10-yl]-4-[2-
(4-methoxyphenyl)-2H-tetrazol-5-yl]butan-2-ol ((+)-3f) 
This compound was obtained from (+)-10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-N,N-diethyl-10H-phenothiazin-2-amine 
((+)-9f, 0.29 g, 0.39 mmol). The crude product was purified by 
column chromatography on silica gel using the eluent 
chloroform to give a white amorphous solid, 0.18 g (88%); ee: 
74%; [α] 25D  = + 9.32 (c 0.352, chloroform); HPLC: using the 
eluent n-hexane:2-propanol + 0.1% diethylamine = 70:30, 
retention time: 9.5 min. 
 
(+)-4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-(2-
morpholin-4-yl-10H-phenothiazin-10-yl)butan-2-ol ((+)-3h) 
This compound was obtained from (+)-10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-morpholin-4-yl-10H-phenothiazine ((+)-
9h, 0.28 g, 0.36 mmol). The crude product was purified by 
flash chromatography on silica gel using the eluent chloroform, 
then chloroform:methanol = 50:1 to give white amorphous 
solid, 0.16 g (84%); ee: 73.4%; [α] 25D  = + 9.92 (c 0.277, 
chloroform); HPLC: using the eluent n-hexane:2-propanol + 
0.1% diethylamine = 70:30, retention time: 11.8 min. 
 
(+)-4-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]-1-[2-(4-
methylpiperazin-1-yl)-10H-phenothiazin-10-yl]butan-2-ol 
((+)-3i) 
This compound was obtained from (+)-10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-(4-methylpiperazin-1-yl)-10H-
phenothiazine ((+)-9i, 0.39 g, 0.49 mmol). The crude product 
was purified by column chromatography on silica gel using the 
eluent chloroform:methanol = 30:1, 15:1 then 10:1 to give a 
brown oil, 0.22 g (83%), ee: 72%; [α] 25D  = + 6.21 (c 0.346, 
chloroform); HPLC: using the eluent n-hexane:2-propanol + 
0.1% diethylamine = 70:30, retention time: 17.3 min. 
 
General procedure for the preparation of (-)- and (+)-
10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine ((-)-8) and (+)-8) 
The procedure followed the aforementioned preparation of 
racemic 10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine (8). 
 
(-)-10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine ((-)-8) 
This compound was obtained from (-)-1-(2-chloro-10H-
phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butan-2-ol ((-)-5, 1.60 g, 3.33 mmol) as white crystals, 2.35 
g (98%); ee: 99.9+% ; [α] 25D  = + 31.20 (c 0.353, chloroform); 
HPLC: using the eluent n-hexane:2-propanol + 0.1% 
diethylamine = 98:2; retention time: 14.5 min; νmax (KBr)/cm-1: 
3071, 2932, 1516, 1456 and 1255. 
 
(+)-10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-chloro-10H-
phenothiazine ((+)-8) 
This compound was obtained from (+)-1-(2-chloro-10H-
phenothiazin-10-yl)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-
yl]butan-2-ol ((+)-5, 1.60 g, 3.33 mmol) as white crystals, 2.35 
g (98%); ee: 74%; [α] 25D = - 22.80 (c 0.440, chloroform); 
HPLC: using the eluent n-hexane:2-propanol + 0.1% 
diethylamine = 98:2, retention time: 12.4 min; νmax (KBr)/cm-1: 
3070, 2958, 1516, 1456 and 1255. 
 
General procedure for the preparation of 10-(2-{[tert-
butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-10H-phenothiazin-2-amine derivatives 
((-)-9 and (+)-9) 
The procedure followed the aforementioned preparation of 
racemic 10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-10H-phenothiazin-2-
amine (9). 
 
(-)-10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-N,N-diethyl-10H-
phenothiazin-2-amine ((-)-9f) 
This compound was obtained from the reaction of (-)-10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine ((-)-8, 0.50 g, 
0.67 mmol) and diethylamine (0.15 mL, 1.40 mmol). The 
crude product was purified by column chromatography on 
silica gel using the eluent n-hexane:ethyl acetate = 2:1 to give 
brown amorphous solid, 0.24 g (45%); ee: 99.9+%; mp 64-70 
°C; [α] 25D  = + 7.39 (c 0.299, chloroform); HPLC: using the 
 eluent n-hexane:2-propanol + 0.1% diethylamine = 75:25, 
retention time: 9.6 min; νmax (KBr)/cm-1: 2964, 2930, 1598, 
1516 and 1466. 
 
(-)-10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-morpholin-4-yl-
10H-phenothiazine ((-)-9h) 
This compound was obtained from the reaction of (-)-10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine ((-)-8, 0.40 g, 
0.55 mmol) and morpholine (0.10 mL, 1.11 mmol). The crude 
product was purified by column chromatography on silica gel 
using the eluent n-hexane:ethyl acetate = 4:1 to give beige 
amorphous solid, 0.35 g (82%); mp 72-80 °C; [α] 25D  = + 11.13 
(c 0.289, chloroform); HPLC: using the eluent n-hexane:2-
propanol + 0.1% diethylamine = 75:25, retention time: 18.6 
min; νmax (KBr)/cm-1: 3429, 2957, 2855, 1595 and 1516. 
 
(-)-10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-(4-
methylpiperazin-1-yl)-10H-phenothiazine ((-)-9i) 
This compound was obtained from the reaction of (-)-10-(2-
{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-2H-
tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine ((-)-8, 0.40 g, 
0.56 mmol) and N-methyl-piperazine (0.12 mL, 1.11 mmol). 
The crude product was purified by column chromatography on 
silica gel using the eluent chloroform:methanol = 20:1, 15:1 
then 10:1 to give beige amorphous solid, 0.31 g (71%); mp 66-
74 °C; [α] 25D = + 11.50 (c 0.264, chloroform). HPLC: using the 
eluent n-hexane:2-propanol + 0.1% diethylamine = 75:25, 
retention time: 20.5 min; νmax (KBr)/cm-1: 2932, 2855, 1584, 
1516 and 1461. 
 
(+)-10-(2-{[tert-Butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-N,N-diethyl-10H-
phenothiazin-2-amine ((+)-9f) 
This compound was obtained from the reaction of (+)-10-
(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-
2H-tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine ((+)-8, 
0.50 g, 0.70 mmol) and diethylamine (0.15 mL, 1.40 mmol). 
The crude product was purified by column chromatography on 
silica gel using the eluent n-hexane:ethyl acetate = 2:1 to give 
beige amorphous solid, 0.34 g (65%); mp 65-70 °C; ee: 78%; 
[α] 25D = - 6.42 (c 0.265, chloroform); HPLC: using the eluent 
n-hexane:2-propanol + 0.1% diethylamine = 75:25, retention 
time: 10.2 min; νmax (KBr)/cm-1: 2964, 2856, 1598, 1516 and 
1466. 
 
(+)-10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-morpholin-4-yl-
10H-phenothiazine ((+)-9h) 
This compound was obtained from the reaction of (+)-10-
(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-
2H-tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine ((+)-8, 
0.40 g, 0.56 mmol) and morpholine (0.10 mL, 1.11 mmol). The 
crude product was purified by flash chromatography on silica 
gel using the eluent n-hexane:ethyl acetate = 4:1 to give beige 
amorphous solid, 0.34 g (79%); mp 78-80 °C; [α] 25D  = - 11.57 
(c 0.271, chloroform); HPLC: using the eluent n-hexane:2-
propanol + 0.1% diethylamine = 75:25, retention time: 19.5 
min; νmax (KBr)/cm-1: 2958, 2856, 1596, 1516 and 1462. 
 
(+)-10-(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-
methoxyphenyl)-2H-tetrazol-5-yl]butyl)-2-(4-
methylpiperazin-1-yl)-10H-phenothiazine ((+)-9i) 
This compound was obtained from the reaction of (+)-10-
(2-{[tert-butyl(diphenyl)silyl]oxy}-4-[2-(4-methoxyphenyl)-
2H-tetrazol-5-yl]butyl)-2-chloro-10H-phenothiazine ((+)-8, 
0.40 g, 0.56 mmol) and N-methylpiperazine (0.12 mL, 1.11 
mmol). The crude product was purified by column 
chromatography on silica gel using the eluent 
chloroform:methanol = 20:1, 15:1 then 10:1 to give beige 
amorphous solid, 0.33 g (75%); mp 65-72 °C; [α] 25D = - 7.75 (c 
0.299, chloroform); HPLC: using the eluent n-hexane:2-
propanol + 0.1% diethylamine = 75:25, retention time: 23.5 
min; νmax (KBr)/cm-1: 2932, 2855, 1584, 1516 and 1461. 
 
Ethyl 4-(5-{3-hydroxy-4-[2-(trifluoromethyl)-10H-
phenothiazin-10-yl]butyl}-2H-tetrazol-2-yl)benzoate (20e) 
To a solution of ethyl 4-(5-{(1Z,3E)-4-[2-(trifluoromethyl)-
10H-phenothiazin-10-yl]buta-1,3-dien-1-yl}-2H-tetrazol-2-
yl)benzoate11 (0.56 g, 1 mmol) in abs. THF (10 mL) in a dried, 
round-bottomed flask equipped with a side arm and cooled to 0 
°C in an argon atmosphere was added BH3xMe2S (0.4 mL, 4 
mmol) dropwise by injection. After addition, the resulting 
yellow suspension was allowed to warm up to rt and 
maintained at this temperature for prolongued time. After the 
completion of the reation (1 d, monitored by TLC), the 
reaction mixture was evaporated, then methanol (15 mL) was 
given to the residue, and stirred for 3 weeks. The reaction 
mixture was contentrated in vacuo and purified by flash 
chromatography on silica gel using the eluent 
dichloromethane, then n-hexane:ethyl acetate = 2:1. The crude 
product (foam) was triturated with diethyl ether and few drops 
of n-hexane, the mixture was cooled whereupon crystals 
deposited. The product was collected by filtration as white 
crystals, 0.11 g (19%); mp 107-108 °C; (Found: C, 58.50; H, 
4.30; N, 12.84; C27H24F3N5O3S requires: C, 58.37; H, 4.35; N, 
12.61%); m/z (EI) [M+H]+: 556.30 (C27H24F3N5O3S requires 
555.16); νmax (KBr)/cm-1: 3394, 1720, 1425, 1272 and 1125; δH 
(300 MHz, CDCl3) 1.44 (3H, t, J = 7.2 Hz), 2.08 (1H, m), 2.25 
(1H, m), 2.63 (1H, br. s), 3.17-3.25 (2H, m), 3.90-4.18 (3H, 
m), 4.43 (2H, q, J = 7.2 Hz), 6.94-7.28 (7H, m), 8.14-8.24 (4H, 
m); δC (75 MHz, CDCl3) 14.3, 21.8, 28.0, 32.1, 53.9, 61.5, 
66.3, 112.6, 116.4, 119.4 (2C), 119.8, 123.8, 125.6, 127.8, 
127.9, 128.0, 130.0, 130.4, 131.0 (2C), 131.3; 139.5, 144.2, 
145.9, 165.4, 166.9. 
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